

**SEMMELWEIS EGYETEM  
DOKTORI ISKOLA**

**Ph.D. értekezések**

**3404.**

**GARAI RÉKA**

**Gyermekekori betegségek klinikuma, élettana és prevenciója**  
című program

Program- és témavezető: Dr. Szabó Attila József, egyetemi tanár

**PEDIATRIC VIRAL INFECTION CONTROL:  
STRATEGIES FOR PREVENTION AND LONG-TERM  
SEQUELAE**

**Ph.D. Thesis**

Translational Medicine Program  
Pharmaceutical Sciences and Health Technologies Division

**Réka Garai, M.D.**

SEMMELWEIS UNIVERSITY



Supervisor:

Attila József Szabó M.D., DSc., Med.habil.

Official reviewers:

Alexandra Katalin Csernus M.D., PhD

Gabriella Bottari M.D., PhD

Head of the Complex Examination Committee:

György Reusz, M.D., PhD., DSc.

Members of the Complex Examination Committee:

Antal Dezsőfi-Gottl M.D. Med.habil.,

Katalin Müller M.D. PhD,

Dániel Veres M.D., PhD,

Michael Wilschanski, M.D., PhD

Budapest

2026



*“Discovery consists of seeing what everybody  
has seen and thinking what nobody has  
thought.”*

Albert Szent-Györgyi

## TABLE OF CONTENTS

<b>1. LIST OF ABBREVIATIONS</b> .....	<b>7</b>
<b>2. STUDENT PROFILE</b> .....	<b>9</b>
2.1. Vision and mission statement, specific goals .....	9
2.2. Future plans .....	10
<b>3. SUMMARY OF THE THESIS</b> .....	<b>11</b>
<b>4. GRAPHICAL ABSTRACT</b> .....	<b>12</b>
<b>5. INTRODUCTION</b> .....	<b>13</b>
5.1. Overview of the topic .....	13
5.2. What is the problem to solve? .....	13
5.2.1. Influenza .....	13
5.2.2. SARS-CoV-2 and Long COVID .....	16
5.3. What is the importance of the topic? .....	19
5.3.1. Influenza .....	19
5.3.2. Long COVID .....	19
5.4. What would be the impact of our research results?.....	19
5.4.1. Impact on Influenza Prevention.....	19
5.4.2. Impact on Long COVID Clinical Care.....	19
5.4.3. Impact on Policy.....	20
5.4.4. Impact on Future Research .....	20
<b>6. OBJECTIVES</b> .....	<b>21</b>
6.1. Study I. – Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis.....	21
6.2. Study II. – Clinical assessment of children with long COVID syndrome.....	21
<b>7. METHODS</b> .....	<b>22</b>
7.1. Study I. - Influenza vaccination.....	22

7.1.1.	Methodology and Protocol .....	22
7.1.2.	Eligibility Criteria.....	22
7.1.3.	Information Sources and Search Strategy .....	22
7.1.4.	Study Selection and Data Extraction .....	23
7.1.5.	Risk of Bias and Quality of Evidence Assessment .....	23
7.1.6.	Data Synthesis and Analysis .....	23
7.1.7.	Subgroup analyses .....	24
7.2.	Study II. – Long COVID .....	24
7.2.1.	Study Design .....	24
7.2.2.	Study Setting .....	24
7.2.3.	Ethics and Patient Consent .....	24
7.2.4.	Participants .....	25
7.2.5.	Variables and Data Sources .....	25
7.2.6.	Questionnaires and symptom mapping .....	25
7.2.6.1.	<b>Clinical and laboratory variables.....</b>	<b>26</b>
7.2.7.	Standardized definitions .....	27
7.2.8.	Bias, Confounding, and Evidence Synthesis .....	27
7.2.9.	Statistical Methods .....	27
<b>8.</b>	<b>RESULTS.....</b>	<b>28</b>
8.1.	Study I - Influenza .....	28
8.1.1.	Study Search and Selection .....	28
8.1.2.	Primary Outcome.....	33
8.1.2.1.	<b>Laboratory-confirmed influenza.....</b>	<b>33</b>
8.1.3.	Secondary Outcomes .....	35
8.1.3.1.	<b>Safety .....</b>	<b>35</b>
d)	<b>Adverse Events (AEs).....</b>	<b>35</b>

e)	<b>Specific Adverse Events</b> .....	35
8.1.3.2.	<b>Cost-effectiveness</b> .....	37
8.1.4.	Risk of Bias Assessment .....	37
8.1.5.	Quality of Evidence .....	38
8.1.6.	Quality of Evidence .....	38
8.2.	Study II – Long COVID .....	38
8.2.1.	Study Population .....	38
8.2.2.	Primary Outcomes .....	39
8.2.2.1.	<b>Symptom scale</b> .....	39
8.2.2.1.	<b>Corresponding medical findings</b> .....	42
8.2.3.	Secondary Outcomes .....	43
8.2.3.1.	<b>Physical examination and laboratory testing</b> .....	43
8.2.3.2.	<b>Autoimmune thyroiditis</b> .....	43
8.2.3.3.	<b>Cardio-pulmonary assessments</b> .....	44
8.2.3.4.	<b>Neurologic evaluations</b> .....	44
8.2.3.5.	<b>Gastrointestinal evaluations</b> .....	44
8.2.3.6.	<b>Dermatologic consultations</b> .....	44
8.2.3.7.	<b>Mental health</b> .....	44
8.2.3.8.	<b>Quality of Life (Functioning)</b> .....	44
8.2.4.	Subgroup and Sensitivity Analyses .....	46
8.2.4.1.	<b>Sex</b> .....	46
8.2.4.2.	<b>Age</b> .....	46
8.2.4.3.	<b>Symptom-onset timing</b> .....	46
8.2.5.	Additional Findings or Exploratory Analyses .....	46
8.2.5.1.	<b>Symptom mapping</b> .....	46
8.2.5.2.	<b>Acute vs. long</b> .....	47

8.2.5.3.	<b>Diagnostic imaging .....</b>	<b>47</b>
<b>9.</b>	<b>DISCUSSION.....</b>	<b>48</b>
9.1.	Summary of Findings, International Comparisons.....	48
9.1.1.	Prevention: Influenza Vaccination .....	48
9.1.2.	Long COVID .....	49
9.1.3.	Integrated Perspective.....	51
9.2.	Strengths .....	51
9.3.	Limitations.....	52
9.3.1.	Influenza Vaccination.....	52
9.3.2.	Long COVID .....	53
<b>10.</b>	<b>CONCLUSIONS.....</b>	<b>55</b>
10.1.	Study I. – Influenza vaccination .....	55
10.2.	Study II. – Long COVID .....	55
<b>11.</b>	<b>IMPLICATIONS FOR PRACTICE.....</b>	<b>56</b>
11.1.	Study I. - Influenza vaccination.....	56
11.2.	Study II. – Long COVID .....	56
<b>12.</b>	<b>IMPLICATIONS FOR RESEARCH .....</b>	<b>58</b>
12.1.	Study I. – Influenza vaccination .....	58
12.2.	Study II. – Long COVID .....	58
<b>13.</b>	<b>IMPLICATIONS FOR POLICY MAKERS .....</b>	<b>59</b>
13.1.	Study I. - Influenza vaccination.....	59
13.2.	Study II. – Long COVID .....	59
<b>14.</b>	<b>FUTURE PERSPECTIVES .....</b>	<b>61</b>
<b>15.</b>	<b>REFERENCES .....</b>	<b>62</b>
<b>16.</b>	<b>BIBLIOGRAPHY.....</b>	<b>76</b>
16.1.	Publications Related to the Thesis.....	76

16.2. Publications not Related to the Thesis.....	76
<b>17. ACKNOWLEDGEMENTS .....</b>	<b>78</b>

## 1. LIST OF ABBREVIATIONS

<b>AE</b>	Adverse Event
<b>ATG</b>	Anti-Thyroglobulin Antibody
<b>ATPO</b>	Anti-Thyroid Peroxidase Antibody
<b>BNP</b>	B-Type Natriuretic Peptide
<b>CAR</b>	Cardiological
<b>CI</b>	Confidence Interval
<b>CENTRAL</b>	Cochrane Central Register of Controlled Trials
<b>CLoCk</b>	Children and Young People with Long COVID
<b>COVID-19</b>	Coronavirus Disease·2019
<b>CRF</b>	Case Report Form
<b>CRP</b>	C-Reactive Protein
<b>CSF</b>	Cerebrospinal Fluid
<b>CT</b>	Computed Tomography
<b>DER</b>	Dermatologic
<b>ECG</b>	Electrocardiogram
<b>EEG</b>	Electroencephalogram
<b>ENT-O</b>	Ear–Nose–Throat and Ophthalmology
<b>GEN</b>	General
<b>GIS</b>	Gastrointestinal
<b>GRADE</b>	Grading of Recommendations Assessment Development and Evaluation
<b>I<sup>2</sup></b>	Higgins' Heterogeneity·Statistic
<b>IgG</b>	Immunoglobulin G
<b>IgM</b>	Immunoglobulin M
<b>IIV</b>	Inactivated Influenza Vaccine
<b>IL-6</b>	Interleukin-6
<b>LAIV</b>	Live Attenuated Influenza Vaccine
<b>LDH</b>	Lactate Dehydrogenase
<b>MAX</b>	Maximum
<b>MEDLINE</b>	Medical Literature Analysis and Retrieval System Online
<b>MIN</b>	Minimum

<b>MRI</b>	Magnetic Resonance Imaging
<b>MUS</b>	Musculoskeletal
<b>NASEM</b>	National Academies of Sciences, Engineering, and Medicine
<b>NEU</b>	Neurologic
<b>NICE</b>	National Institute for Health and Care Excellence
<b>NT-pro-BNP</b>	N-Terminal Pro-B-Type Natriuretic Peptide
<b>OR</b>	Odds Ratio
<b>PRISMA</b>	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
<b>PROSPERO</b>	International Prospective Register of Systematic Reviews
<b>QoL-F</b>	Quality of Life – Functioning
<b>REP</b>	Reproductive
<b>RCT</b>	Randomized Controlled Trial
<b>RoB2</b>	Revised Cochrane Risk-of-Bias Tool for Randomized Trials
<b>PCR</b>	Polymerase Chain Reaction
<b>PSY</b>	Psychological
<b>PUL</b>	Pulmonary
<b>SAE</b>	Serious Adverse Event
<b>SARS-CoV-2</b>	Severe Acute Respiratory Syndrome Coronavirus 2
<b>SD</b>	Standard Deviation
<b>TRAK</b>	Thyroid Stimulating Hormone Receptor Antibody
<b>TSH</b>	Thyroid Stimulating Hormone
<b>US</b>	Ultrasound
<b>USA/U.S.</b>	United States of America
<b>WHO</b>	World Health Organization
<b>6mWT</b>	Six-Minute Walking Test
$\tau^2$	Between-study variance

## 2. STUDENT PROFILE

### 2.1. Vision and mission statement, specific goals

My vision is to contribute to evidence-based pediatric care that is child- and family-friendly and responsive to the complexity of childhood illnesses. I aim to support preventive strategies and clinical management pathways that are not only clinically effective and safe, but also accessible and acceptable for children and families.

My mission was to generate robust comparative evidence that informs pediatric influenza vaccination strategies and to advance structured, science-based approaches to post-viral care in children. Shaped by clinical experience with pediatric long COVID, my work is guided by an integrative perspective that considers both physical and psychological aspects of health, valuing creative, systems-level thinking in addressing complex clinical problems.



### Scientometrics

<b>Number of all publications:</b>	7
Cumulative IF:	30.6
Av IF/publication:	4.37
Ranking (SCImago):	D1:5, Q1:2
<b>Number of publications related to the subject of the thesis:</b>	2
Cumulative IF:	10.6
Av IF/publication:	5.3
Ranking (Sci Mago):	D1:2
<b>Number of citations on Google Scholar:</b>	67
<b>Number of citations on MTMT (independent):</b>	40
<b>H-index:</b>	5

The student's detailed bibliography can be found on pages 75-76.

## **2.2. Future plans**

In the coming years, I aim to further shape my clinical and research path at the intersection of pediatric care and prevention.

In the short term, we have obtained new ethical approval to investigate neutrophil alterations observed in children with long COVID, to assess their temporal dynamics and clinical relevance. This work reflects my intention to pursue both basic and clinical research, linking biological mechanisms to patient-level clinical findings. In parallel, I am actively involved in developing a Hungarian national pediatric quality of life questionnaire to compare children living with chronic diseases with their healthy peers, representing a complementary clinical and patient-centered research direction.

I value collaborative work and enjoy contributing to supportive research environments. I am motivated by the idea that research can be both rigorous and creative, particularly when teams actively support one another's growth. For this reason, I hope that within the framework of the Semmelweis Pediatric Research and Innovation Group (SPRING), we can pursue ambitious goals and help others experience the intellectual and human value of collaborative research.

### **3. SUMMARY OF THE THESIS**

Pediatric viral infections challenge healthcare systems not only through acute disease but also through their long-term consequences. Young children and those with comorbidities are a high-risk group for severe deterioration. Moreover, children are key drivers of transmission and may develop post-infectious sequelae, underscoring the need for pediatric-focused evidence to inform effective infection control.

This thesis combines two research directions that have emerged from clinical practice: the optimization of preventive strategies for influenza and the structured clinical understanding of pediatric long COVID. While these topics address different stages of viral disease, they are linked by a shared aim to improve child-friendly, evidence-based care.


Our first study synthesizes randomized evidence comparing live attenuated intranasal (LAIV) and inactivated influenza vaccines (IIV) in children. The results demonstrate comparable overall effectiveness and favorable safety profiles. However, data from large clinical trials and economic models indicate that intranasal vaccination is superior. The needle-free administration of LAIV is associated with higher acceptability among children, facilitating its integration into pediatric immunization programs, where increased uptake may translate into broader population-level benefits. Our second study presents a cross-sectional clinical characterization of a new entity, pediatric long COVID. Despite predominantly mild acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, children experienced numerous persistent symptoms with substantial change in their functioning, while rates of objective clinical findings were limited. In the absence of reliable biomarkers or targeted therapies, these findings highlight the need for equitable access to comprehensive pediatric long COVID services. Furthermore, the identification of autoimmune conditions highlights the importance of ongoing surveillance and targeted research to better understand long-term post-viral outcomes in children.

Taken together, the results highlight the importance of integrating effective, child-friendly prevention strategies with structured, evidence-based approaches to recognizing and managing long-term sequelae in pediatric infectious diseases.


#### 4. GRAPHICAL ABSTRACT

# PEDIATRIC VIRAL INFECTION CONTROL: STRATEGIES FOR PREVENTION AND LONG-TERM SEQUELAE

### CONTEXT




### INFLUENZA PREVENTION



### POLICY IMPLICATIONS

1. Policies should promote child-friendly influenza vaccination options reducing barriers limiting vaccine uptake.
2. Health systems should recognize pediatric long COVID and ensure access to coordinated, multidisciplinary care for affected children.

### LONG -TERM SEQUELAE



Created with BioRender Poster Builder

## **5. INTRODUCTION**

### **5.1. Overview of the topic**

Respiratory viral infections pose a significant global health burden, resulting in substantial morbidity, mortality, and economic impact worldwide (1,2). While most viral respiratory infections are self-limiting, severe acute disease and long-term sequelae have long been recognized for pathogens such as influenza-, respiratory syncytial-, and coronaviruses, occasionally leading to persistent pulmonary and/or extrapulmonary sequelae affecting multiple organ systems, resulting in prolonged functional impairment and reduced quality of life (3–13).

This thesis investigates pediatric respiratory viral infections from two complementary perspectives. One part focuses on influenza immunization strategies, while the other addresses post-infectious sequelae of SARS-CoV-2, each contributing to pediatric healthcare from a different angle.

### **5.2. What is the problem to solve?**

#### ***5.2.1. Influenza***

Seasonal influenza causes annual epidemics of varying severity. While most infected individuals develop acute respiratory symptoms and recover within a week, influenza may cause severe or even fatal complications, particularly in vulnerable populations such as young children or individuals living with chronic diseases (8).

Waning host immunity and continuous antigenic drift of circulating influenza A and B viruses necessitate the annual reformulation of vaccines, which remains the primary preventive strategy (Table 1) (8,14). Although non-pharmaceutical public health interventions substantially altered influenza epidemiology during the SARS-CoV-2 pandemic (8,15,16), pediatric transmission remained relatively stable according to U.S. data (17), underscoring the importance of immunization (8,14).

Despite this, national vaccination policies differ substantially not only across the globe but also within Europe. It was only recently that all European Union/European Economic Area countries began recommending vaccinating children, either on an age- or risk-based basis. In the latter group, vaccination is advised primarily for children with underlying

medical conditions, whereas in countries with age-based policies, recommendations generally focus on young children, most commonly those under 5 years of age (18). Despite this expansion in recommendations, the median vaccine coverage rate was 6.9% as per the European Centre for Disease Prevention and Control's report on the 2024/2025 season (18). In comparison, influenza vaccination coverage among children in the United States was 49.2% during the 2024–2025 season, a decrease from 2019/2020 (13).

While coverage remains a critical factor, vaccine effectiveness is also strongly influenced by vaccine strain composition, which historically evolved toward quadrivalent formulations to broaden the protection by including both the two influenza B and A lineages (Table 1); however, regulatory agencies have recently recommended a return to trivalent formulations containing two A strains and a single B influenza lineage (19–21). In addition to strain selection, influenza vaccination strategies in children differ according to formulation and route of administration (Table 1). LAIV offers several theoretical advantages, including needle-free delivery, ease of administration, and potentially higher acceptability (13,22–24). Nevertheless, its global availability varies widely, ranging from fully funded school-based programs to complete absence in many regions (13,25–28). Moreover, compared with IIV, the use of LAIV is considerably more restricted, and it is more expensive (Table 1) (8,29,30).

**Table 1. Influenza vaccine types for children (8,30,32,33)**

	<b>Inactivated influenza vaccine (IIV)</b>	<b>Live-attenuated influenza vaccine (LAIV)</b>
<b>Route of administration</b>	Intramuscular or subcutaneous	Intranasal
<b>Approved age range</b>	≥6 months	2–17 years (Europe) / 2–49 years (USA)
<b>Dosing schedule</b>	<9 years (first vaccination): ≥9 years: one dose annually	two doses ≥ 4 weeks apart
<b>Contraindications</b> (might differ according to regions)(14,31)	History of anaphylaxis after a previous dose or vaccine component	History of anaphylaxis after a previous dose or vaccine component, Pregnancy, Immunosuppression (including close contacts of severely immunosuppressed individuals), Aspirin or salicylate use, Recent antiviral use (oseltamivir or zanamivir within 48 h; peramivir within 5 days; baloxavir within 17 days), Age 2–4 years with asthma diagnosis or wheezing in the previous 12 months, Active cerebrospinal fluid leak or oropharyngeal communication Cochlear implant, Anatomic or functional asplenia
<b>Relative cost (approx.)</b>	Lower (\$6.49–\$10)	Higher (\$24–\$29)


Prior to our work, existing evidence on pediatric vaccine performance was dominated by data from observational studies, demonstrating heterogeneous and geographically variable effectiveness, with limited distinction between pediatric and adult outcomes (34,35). Moreover, while efficacy against placebo has been demonstrated for trivalent influenza vaccines, suggesting that LAIV has superior efficacy, data on quadrivalent vaccines are controversial (21,35). Still, comparative evidence directly assessing their relative performance in pediatric populations is limited (34,35). Moreover, prior reviews lacked quadrivalent head-to-head randomized controlled trials and did not comprehensively address safety or cost-effectiveness outcomes (36). Differences in accessibility, eligibility criteria, and associated costs, combined with the lack of robust comparative pediatric evidence, have contributed to substantial international variation in vaccination policies, funding structures, and coverage rates, which remain below the

WHO’s recommended 75% uptake (37–39). Thus, there is a need to support strategies that are not only effective and safe but also associated with higher acceptance.

### 5.2.2. SARS-CoV-2 and Long COVID

At the initiation of our study in the early months of 2021, published evidence regarding the long-term effects of SARS-CoV-2 infection, commonly referred to as “long COVID,” was limited. Available reports consisted mainly of anecdotal descriptions and small observational studies. These studies employed heterogeneous case definitions, had limited follow-up periods, and applied inconsistent outcome measures. Consequently, reported estimates of prevalence, symptom profiles, and risk factors varied widely and were affected by selection and ascertainment bias. At that time, frameworks and clinical guidelines were primarily derived from adult populations (40–43).

The National Institute for Health and Care Excellence (NICE) guideline provided one of the earliest structured case definitions, distinguishing between different phases of COVID-19 (Figure 1). They described the condition as a set of signs and symptoms that develop during or after an acute infection, persist for more than four weeks, and are not explained by an alternative diagnosis (44,45). However, their applicability to pediatric populations remained uncertain. In the absence of a validated child-specific research case definition before 2022 (46), and with a pediatric clinical criteria published by the World Health Organization only in 2023 (47), the umbrella term “*long COVID*” was commonly used to encompass both ongoing symptomatic COVID-19 and post-COVID-19 syndrome in children at the time our research was conducted (Figure 1). (44,45).



**Figure 1. Case definitions of long-term consequences following COVID-19 according to the NICE guideline**

After the WHO’s adult definition of post-COVID condition developed by a Delphi process was published in October 2021 (48), the Children and Young People with Long

COVID (CLOcK) consortium proposed a research definition for children in April 2022, while the World Health Organization (WHO) proposed pediatric definitions for clinical use in February 2023 (46,47). Although all three frameworks require persistent symptoms (new-onset, ongoing, fluctuating, or relapsing) and functional impairment following SARS-CoV-2 infection, they differ in the specific criteria they apply (44,46,47). The CLOcK definition of pediatric post-COVID condition is more restrictive, requiring a confirmed infection, symptom duration of at least 12 weeks, and exclusion of alternative diagnoses, thereby prioritizing methodological specificity (46). In contrast, the WHO definition of pediatric post-COVID is clinically oriented, allows for both confirmed and probable infection, requires symptoms lasting at least two months with onset within three months of acute COVID-19, and permits the presence of additional diagnoses, supporting broader applicability in real-world pediatric care. The WHO also highlights the main symptoms: fatigue, changed or decreased smell, and anxiety (47). Both of these pediatric criteria underline the detrimental effect of long COVID on children's quality of life (46,47).

The U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) proposed the most recent comprehensive definition for long COVID in 2024 (49). According to their criteria, long COVID is an infection-associated chronic condition that persists for at least three months after SARS-CoV-2 infection and may manifest as a continuous, relapsing–remitting, or progressive disease affecting one or more organ systems. They emphasize the considerable clinical heterogeneity of the condition, recognizing that it may present with a wide spectrum of symptoms, including fatigue, post-exertional malaise, cognitive impairment, sleep disturbances, autonomic symptoms, and respiratory complaints, or develop diagnosable conditions such as dysautonomia, myalgic encephalomyelitis/chronic fatigue syndrome, or autoimmune disorders. Importantly, the definition highlights that Long COVID may follow an acute infection of any severity, may present immediately or with a delayed onset, and can affect individuals across all age groups, including children. Furthermore, it is clinically diagnosed, as no definitive biomarker has yet been identified. Also, it may lead to substantial functional impairment affecting daily activities, school attendance, and quality of life (49).

The NICE guideline also outlined early approaches for identification, assessment, and management, emphasizing multidisciplinary care, exclusion of alternative diagnoses, and

rehabilitation, aiding both our clinical and research roles at the beginning of the long COVID era (44,45).

At the time our study was accepted for publication, available scientific data were still derived from studies often lacking comprehensive clinical characterization, standardized follow-up, or laboratory confirmation of acute infection (50–52). Long-term outcomes affecting various organ systems were typically investigated separately, limiting an integrated understanding of the condition (53–55). Given the absence of systematic pediatric-specific clinical knowledge on long COVID and the emerging evidence suggesting that long COVID may differ in children compared with adults (56), child-specific systematic clinical data were required to better define the natural history and clinical spectrum of pediatric long COVID and to support the development of evidence-based guidelines.

### **5.3. What is the importance of the topic?**

#### ***5.3.1. Influenza***

As children are key drivers of respiratory virus transmission, improving prevention among this age group has broad population-level benefits, including protection of other vulnerable subjects and a reduction in healthcare burden (57). To achieve such goals, we need to design cost-effective and highly acceptable, effective, and safe childhood vaccination programs; thus, understanding the comparative performance of available influenza vaccines is critical.

#### ***5.3.2. Long COVID***

Pediatric long COVID represents a significant and emerging public health issue, as it has been estimated that approximately 10–20% of children may experience persistent symptoms following an otherwise mild acute infection. Given the large number of children infected worldwide, even a relatively low prevalence of post-acute symptoms corresponds to a substantial absolute burden for affected children, families, and health care systems, with effects likely to extend far beyond the immediate period. Persistent symptoms may interfere with physical functioning, cognitive performance, school attendance, psychosocial well-being, and overall quality of life during critical stages of development (58,59).

### **5.4. What would be the impact of our research results?**

#### ***5.4.1. Impact on Influenza Prevention***

In the context of insufficient vaccination coverage, options that may improve vaccine uptake, including pain-free administration methods, could provide substantial long-term benefits (39,57). Thus, by synthesizing comparative evidence on influenza vaccination, this work provides policymakers with data relevant to optimizing pediatric vaccination strategies.

#### ***5.4.2. Impact on Long COVID Clinical Care***

The pandemic presented an unprecedented opportunity to study post-viral syndromes on a large scale, enabling early and detailed clinical characterization of persistent symptoms

following acute COVID-19. These findings can guide the development of structured assessment pathways and child-specific case definitions.

#### ***5.4.3. Impact on Policy***

This work provides evidence relevant to future policymaking on both pediatric influenza vaccination strategies and organized post-viral care systems.

#### ***5.4.4. Impact on Future Research***

The findings reveal important evidence gaps in pediatric long COVID and support hypothesis generation for future research, as well as provide methodological insights for future vaccine studies.

In summary, the combined findings may improve pediatric influenza protection programs and how we support those experiencing prolonged COVID-19-related symptoms, ultimately contributing to healthier childhoods and more resilient healthcare systems.

## **6. OBJECTIVES**

### **6.1. Study I. – Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis**

The first study aimed to evaluate the comparative effectiveness, safety, and cost-effectiveness of LAIV relative to IIV in pediatric populations by synthesizing current evidence.

### **6.2. Study II. – Clinical assessment of children with long COVID syndrome**

The second study investigated the clinical characteristics and symptom patterns associated with pediatric long COVID in an observational cohort.

## **7. METHODS**

### **7.1. Study I. - Influenza vaccination**

#### **7.1.1. *Methodology and Protocol***

Our review was conducted in accordance with the PRISMA recommendations (60). The protocol was preregistered in PROSPERO (CRD42021285412), from which minor deviations were implemented to increase the clinical relevance and completeness of the dataset. Specifically, we expanded the eligible age range to 21 years and supplemented the dataset with outcomes retrieved from clinical trial registry sites. Additionally, we excluded studies that used mono- or bivalent vaccines, which are no longer in contemporary practice (14). Data on influenza-like illness were insufficient for analysis, and antibody response results were highly heterogeneous with limited real-world applicability (61).

#### **7.1.2. *Eligibility Criteria***

We included randomized, active-controlled trials directly comparing LAIV with IIV in pediatric populations. Studies were eligible if they reported at least one of the following outcomes:

- rates of laboratory-confirmed influenza infection
- safety or reactogenicity events
- numerical cost-effectiveness data

In cases where multiple publications described overlapping datasets, peer-reviewed articles were prioritized.

#### **7.1.3. *Information Sources and Search Strategy***

A comprehensive search was conducted in MEDLINE (via PubMed), Embase, and the Cochrane Register of Controlled Trials (CENTRAL). The final update occurred on 13 November 2023. The used search terms combined concepts of vaccination, influenza, pediatric population, and randomization, using both full keywords and truncations to maximize sensitivity. The reference lists of included papers and relevant reviews were also hand-searched.

#### ***7.1.4. Study Selection and Data Extraction***

Two reviewers independently screened all records using Rayyan.ai (Rayyan Systems Inc., 2020). Following duplicate removal, title and abstract selection and full text retrieval took place in sequence. The agreement between reviewers was quantified using Cohen's Kappa at each stage, and disagreements were resolved through discussion.

Data extraction was carried out independently by two reviewers.

For each study, we collected information on:

- first author and year of publication
- study design, setting
- participant characteristics
- vaccine regimens
- data on eligible outcomes

#### ***7.1.5. Risk of Bias and Quality of Evidence Assessment***

The risk of bias of the included randomized trials was evaluated using the Cochrane RoB 2 tool (RoB-2) (62). The certainty of evidence across outcomes was assessed using the GRADE approach (63). Two independent reviewers carried out both assessments. In the case of disagreements, a third reviewer decided them.

#### ***7.1.6. Data Synthesis and Analysis***

Pooled effect estimates were calculated as odds ratios (ORs), with 95% confidence intervals (CIs), prediction intervals, and p-values using the random-effects Mantel-Haenszel method (64,65). For outcomes where studies with zero events were present, we applied a correction of 0.5 to the cell frequencies to calculate the individual OR. Pooled results were then estimated using the exact Mantel-Haenszel method. Between-study variance ( $\tau^2$ ) was estimated using the Paule-Mandel method with Hartung-Knapp adjustment (66,67). Heterogeneity was assessed using  $I^2$  statistics and its confidence interval, and with the use of the Cochrane's Q test. Data visualizations were performed with forest plots and publication bias was examined using funnel plots ( $\geq 8$  studies) and Egger's test ( $\geq 10$  studies). Sensitivity analyses included leave-one-out procedures.

All analyses were performed in R (version 4.1.2.) using the meta package in line with Harrer et al. with the help of a professional statistician (36,68).

### **7.1.7. Subgroup analyses**

To improve generalizability and to explore the hypothesis that pre-existing immunity and immunological maturation, and the number of added strains, may influence vaccine performance, we did subgroup analyses based on:

- vaccine valency
- study size
- age categories (69,70)

## **7.2. Study II. – Long COVID**

### **7.2.1. Study Design**

We reported on a single-center, observational case series of children and adolescents with long COVID syndrome who attended our dedicated outpatient clinic. The clinical work-up followed a diagnosis-by-exclusion approach, combining routine pediatric assessments with targeted, multidisciplinary investigations. The study was descriptive in nature and did not include a control group.

### **7.2.2. Study Setting**

Our study was conducted at the 1<sup>st</sup> Department of Pediatrics, now known as the Bókay street Unit of the Pediatric Center, Semmelweis University (Budapest, Hungary), where a specialized long COVID clinic for children was launched in March 2021. Data collection spanned from 24 March to 26 May 2021. Families from anywhere in the country could arrange appointments through an online booking system; no referral from a general practitioner or pre-screening was required.

### **7.2.3. Ethics and Patient Consent**

The project was approved by the national medical research ethics committee (ETT TUKEB, approval number IV/5943 – 1/2021/EKU). All assessments were integrated into routine clinical care. Data were collected, anonymized, and analyzed collectively for research purposes. Parents provided informed consent for participation, and children contributed assent appropriate to their age.

#### **7.2.4. Participants**

All consecutive children presenting to the long COVID clinic during the study period were screened for eligibility. Case definition was primarily based on the NICE guideline. They described long COVID syndrome based on compatible clinical or laboratory evidence of prior COVID-19 infection at least one month before the onset of current symptoms, which could not be better explained by an alternative diagnosis. Long COVID in this study encompassed both “ongoing symptomatic COVID-19” (4-12 weeks after acute disease) and “post-COVID-19 syndrome” (>12 weeks) (Figure 1) (44,45). Before data analysis, each case was reviewed by our expert team, and patients were excluded if they did not meet the predefined time criteria or if their symptoms and signs were clearly attributable to an alternative diagnosis or were older than 18 years old. Children with only clinically suspected, but not laboratory confirmed acute infection were also excluded to reduce misclassification.

#### **7.2.5. Variables and Data Sources**

Clinical information was recorded in a standardized case report form (CRF) that integrated:

- medical history
- physical examination
- results of laboratory, imaging, and electrophysiological studies
- specialist consultation reports

#### **7.2.6. Questionnaires and symptom mapping**

The CRF incorporated the WHO Post COVID case report form (71), which was translated and adapted to our local clinical needs. This tool covers:

- characteristics of the acute infection
- persisting new symptoms
- quality of life (functioning)

Before the first visit to the clinic, parents, together with their children, completed this online survey.

Verification of prior COVID-19 by positive polymerase chain reaction (PCR), antigen, or antibody testing was based primarily on parental report; however, spike antibody

testing was performed in all children at a period when no children had been vaccinated against COVID-19, allowing antibody positivity to be interpreted as evidence of prior infection.

Severity of the acute infection was based on the WHO's clinical classification. Mild disease was defined by the absence of hypoxia or pneumonia, while moderate disease included non-severe pneumonia with oxygen saturation  $\geq 90\%$  on room air. Severe disease required clinical signs of severe pneumonia with hypoxia (saturation  $< 90\%$ ) or marked respiratory distress or central cyanosis. Critical disease comprised conditions such as acute respiratory distress syndrome (ARDS), sepsis or septic shock, thromboembolic or cardiovascular complications, or Multisystem Inflammatory Syndrome in Children (MIS-C) (71).

The long COVID symptom module contained 50 items, which were later grouped into ten organ-system categories: general, cardiovascular, neurologic, mental health, gastrointestinal, dermatologic, musculoskeletal, pulmonary, ear-nose-throat and ophthalmologic (ENT-O), and reproductive. Quality of life in terms of functioning (QoL-F) was assessed by 12 items on a 5-point scale from "no difficulty" to "extreme difficulty/cannot do". Each item was also rated relative to the pre-COVID period on a three-level scale ("better/same/worse"). Responses were summarized into two index scores (QoL-F and change in QoL-F), scaled from 0 to 100 while accounting for missing answers (QoL-F: 0 is "no difficulty", 100 is "extreme difficulty"; QoL-F change: 0 is "better", 50 is "unchanged", and 100 is "worse") (71).

#### ***7.2.6.1. Clinical and laboratory variables***

In accordance with NICE recommendations, all children underwent:

- complete physical examination, and
- predefined panel of blood tests, including:
  - o complete blood count,
  - o basic clinical chemistry (electrolytes, liver and renal function markers, C-reactive protein (CRP), creatinine-kinase (CK), total protein, albumin, lactate-dehydrogenase (LDH), ferritin),
  - o Il-6, BNP/NT-proBNP, D-dimer, troponin,

- thyroid function and thyroid autoantibodies (TSH, free T3, T4, anti-thyroperoxidase antibody (anti-TPO), anti-thyroglobulin antibody (anti-TG), TSH receptor antibody (TRAK),
- SARS-CoV-2 IgM, IgG (spike)

Further diagnostic tests, such as imaging (e.g. chest X-ray, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), lung function testing, or specialists' consultations were requested as guided by presenting symptoms and initial findings based on local guidelines.

#### **7.2.7. Standardized definitions**

Laboratory reference ranges were based on age-specific institutional pediatric norms. Chronic medical conditions were defined using discharge diagnoses documented prior to or during the clinic visit. Obesity was characterized using national, age-specific body mass index (BMI) Z-score thresholds.

#### **7.2.8. Bias, Confounding, and Evidence Synthesis**

Several steps were taken to improve internal validity. First, only children with laboratory-confirmed SARS-CoV-2 infection were included, with the application of international case definitions and questionnaires, thereby reducing the risk of misclassification of exposure. Secondly, the questionnaire responses were reviewed and verified by the examining pediatrician, who also documented objective findings in the CRF. Thirdly, children were accepted from all over the county without referral. Finally, data entry from CRFs into analysis datasets was checked and revalidated by the study team and our professional biostatistician.

As an observational case series without a control group, our study was not designed to make causal inferences. Therefore, we only performed a descriptive synthesis. Potential confounders, such as age, sex, and pre-existing conditions, were recorded for context but not adjusted for in the analysis, as no formal comparative analyses were planned.

#### **7.2.9. Statistical Methods**

Data from the CRFs were retrieved into data tables and checked for accuracy in collaboration with a professional biostatistician. Descriptive statistics were used to summarize continuous variables as means  $\pm$  standard deviations (SD), or median and interquartile ranges (IQR). Categorical variables were presented as absolute counts and

percentages (%). Group comparisons between continuous variables were made using independent samples t-tests with Hedges' g effect size, confidence intervals. Associations between continuous variables were examined using Pearson's correlation coefficient. The significance level was set a priori at  $\alpha = 0.05$ . Statistical analyses were performed by our professional biostatistician using IBM SPSS Statistics, version 25.0, and network visualizations were generated with the qgraph package of R (version 1.6.9).

## **8. RESULTS**

### **8.1. Study I - Influenza**


#### ***8.1.1. Study Search and Selection***

The search identified a broad set of eligible trials (n= 3646). After eligibility assessment, 22 studies were included in the systematic review. The meta-analysis incorporated 19 studies, of which eight trials provided data on laboratory-confirmed influenza, and all of them reported on safety outcomes (Figure 2, Table 2).

The majority of the included studies evaluated trivalent formulations of both IIV and LAIV, while data on quadrivalent comparisons were scarce. Notably, no randomized trial compared quadrivalent vaccines. Only one small study contrasted quadrivalent LAIV with a trivalent injectable vaccine (72).

The included studies were highly heterogeneous, encompassing single-center to large multicenter trials conducted over multiple influenza seasons, enrolling participants from infancy through young adulthood (max. 21 years) and including both healthy children and those with a wide range of underlying medical conditions, across different vaccine formulations and study designs (Table 2).

The PRISMA diagram summarizing the screening process is presented in Figure 2 (36).



**Figure 2. PRISMA 2020 flow diagram illustrating the study selection process for the systematic review comparing live-attenuated and inactivated influenza vaccines in children (36)**

**Table 2. Basic characteristics of included studies (36)**

Author (year)	Style	Number of centers	Study period	Mean age (range), in years	Health status	Treatments (dose)	Confirmed influenza (Number of children/event number)	Safety outcomes
Ashkenazi et al. (2006) (73)	Individually randomized, open-label	>100 centers	2002-2003	3.0 (0.5-5.9)	Recurrent respiratory tract infections	TLAIV (2) TIV (2)	1050/29 1035/60	Related and overall serious adverse events, adverse events, hospitalization, subfebrility, fever, sore throat, cough, runny nose, otitis media, irritability, headache, decreased appetite, decreased activity, vomiting, muscle- or body ache, chills
Belshe et al. (2007) (74)	Individually randomized double-blind	>100 centers	2004-2005	(0.5-4.9)	Wheezier 6%	TLAIV (1-2 <sup>a</sup> ) TIV (1-2 <sup>a</sup> )	3916/153 3936/338	Related and overall adverse events, hospitalization, subfebrility, wheezing, runny nose
Carr et al. (2011) (75)	Cluster randomized open-label	<100 centers	2008-2009	10.4 (2.1-21.0)	Cancer	TLAIV (1-2 <sup>b</sup> ) TIV (2)	28/1 27/2	Related and overall serious adverse events, subfebrility, sore throat, cough, runny nose, irritability, headache, decreased activity, vomiting, muscle- or body ache, chills
Fleming et al. (2006) (76)	Individually randomized open-label	>100 centers	2002-2003	11.0 (6-17.9)	Asthma	TLAIV (1) TIV (1)	1111/50 1106/73	Related serious adverse events, adverse events, hospitalization, subfebrility, fever, sore throat, cough, runny nose, otitis media, irritability, headache, decreased appetite, decreased activity, vomiting, upper respiratory tract infections, nasopharyngitis, muscle- or body ache, chills, asthma attack
Hoft et al. (2011) (77)	Individually randomized open-label	<100 centers	2005-2006	(0.5-2.9)	Healthy	TLAIV (2) TIV (2)	Not included	Subfebrility, fever, runny nose
		<100 centers	2006-2007	(1.0-2.9)				
Ilyushina et al. (2015) (78)	Individually randomized open-label	<100 centers	2010-2012	5.4 (2.25-9.7)	Healthy	TLAIV (1-2) TIV (1-2)	13/0 18/0	Subfebrility, fever, upper respiratory tract infections
Krishnan et al. (2021) (79)	Individually randomized triple-blind	<100 centers	2015-2017	(2.0-10.0)	Half of children is malnourished	TLAIV (1) TIV (1-2 <sup>b</sup> )	1087/279 1092/287	Related and overall serious adverse events, subfebrility, irritability, headache, decreased appetite, decreased activity, vomiting, diarrhea

Author (year)	Style	Number of centers	Study period	Mean age (range), in years	Health status	Treatments (dose)	Confirmed influenza (Number of children/event number)	Safety outcomes
Kwong et al. (2015) (80)	Cluster randomized open-label	<100 centers	2013-2014	(4.0-14.0)	Children	TLAIV (1-2 <sup>b</sup> ) TIV (1-2 <sup>b</sup> )	Not included	Adverse events
Levin et al. (2008) (81)	Individually randomized open-label	<100 centers	2004-2005	(5.0-17.9)	HIV	TLAIV (1) TIV (1)	Not included	Skin reactions, nasopharyngitis, ear and eye reactions
Loeb et al. (2016) (82)	Cluster randomized double-blind	<100 centers	2012-2015	(3.0-15.0)	Healthy	TLAIV (1-2 <sup>b</sup> ) TIV (1-2 <sup>b</sup> )	1473/91 1201/77	Related serious adverse events, adverse events, hospitalization, subfebrility, sore throat, skin reactions, runny nose, headache, decreased appetite, vomiting, muscle- or body ache, ear and eye reactions, diarrhea, chills
Luce et al. (2008) (83)	Cost-effectiveness modeling study of data of the 2.0-4.9 years old cohort from the Belshe et al. (2007) <sup>20</sup> study.							
Neuzil et al. (2001) (84)	Individually randomized double-blind	<100 centers	1985-1990	(1.0-16.0)	Healthy	TLAIV (1) TIV (1)	Not included	Related and overall serious adverse events, subfebrility, sore throat, cough, runny nose
Smolen et al. (2014) (85)	Cost-effectiveness modeling study of data from the Ashkenazi et al. (2006) <sup>32</sup> and Fleming et al. (2006) <sup>26</sup> studies.							
Sokolow et al. (2022) (86)	Cluster randomized open-label	<100 centers	2018-2020	(5.0-17.0)	Asthma	QLAIV (1) QTIV (1)	Not included	Runny nose, sore throat, chills, ear and eye reactions, headache, muscle-or body ache, decreased activity, skin reactions, fever, wheezing, asthma attack, cough
Tarride et al. (2012) (87)	Cost-effectiveness modeling study of three age cohorts of Canadian children: 2.0–5.0 years of age, 6.0–9.0 years of age, and 10.0–17.0 years of age. Vaccine efficacy was taken from the Belshe et al. (2007) study <sup>20</sup> .							
EU-CTR 2004-000585-13 (88)	Individually randomized double-blind	>100 centers	2004-2005	(0.5-4.9)	Healthy	TLAIV (1-2 <sup>a</sup> ) TIV (1-2 <sup>a</sup> )	Not included	Mortality, people affected by related serious adverse events, adverse events, skin reactions, otitis media, upper respiratory tract infections, nasopharyngitis, ear and eye reactions, diarrhea, asthma attack
NCT00461981 (89)	Individually randomized open-label	<100 centers	2007-2008	(1.0-2.9)	Healthy	TLAIV (2) TIV (2)	Not included	Related serious adverse events, adverse events, subfebrility, cough, runny nose, vomiting, upper respiratory tract infections, nasopharyngitis, diarrhoea
NCT01194297 (90)	Individually randomized open-label	<100 centers	2010-2011	(2.0-3.0)	Premature, very low birth weight	QLAIV (1) QIV (1)	Not included	Related and overall serious adverse events, adverse events

Author (year)	Style	Number of centers	Study period	Mean age (range), in years	Health status	Treatments (dose)	Confirmed influenza (Number of children/event number)	Safety outcomes
NCT01246999 (91)	Individually randomized open-label	<100 centers	2010-2011	(3.0-9.0)	Healthy and former full-term infants	TLAIV (2) TIV (2)	Not included	Related and overall serious adverse events, subfebrility, sore throat, wheezing, cough, runny nose, headache, decreased activity, muscle- or body ache
NCT02250274 (92)	Individually randomized open-label	<100 centers	2014-2015	10.0 vs.12.0 <sup>d</sup> (5.0-17.0)	Healthy	QLAIV (1) TIV (1)	85/13 46/5	Related and overall serious adverse events
NCT03600428 (93)	Individually randomized open-label	<100 centers	2018-2020	(5.0-11.0)	Asthma	QLAIV (1) QIV (1)	Not included	Mortality, related and overall serious adverse events, wheezing, cough, asthma attack
NCT03982069 (94)	Individually randomized open-label	<100 centers	2019-2021	(4.0-21.0)	Healthy	QLAIV (1) QIV (1)	Not included	Mortality, related and overall serious adverse events, adverse events

TLAIV: trivalent live attenuated influenza vaccine; TIV: trivalent inactivated influenza vaccine; QLAIV: quadrivalent live attenuated influenza vaccine; QIV: quadrivalent inactivated influenza vaccine

<sup>a</sup>Second dose, if none before

<sup>b</sup>Second dose, if <9 years old, less than 2 prior vaccinations

<sup>c</sup>Second dose, if post-vaccination serum HAI titers against H1N1 and H3N2  $\leq$  8 were revaccinated

<sup>d</sup>Mean age was 10 in the LAIV group, 12 in the TIV


### 8.1.2. Primary Outcome

#### 8.1.2.1. Laboratory-confirmed influenza

Across trivalent comparisons, based on data of more than 15,000 participants, the overall pooled estimate showed no statistically significant difference between LAIV and IIV in preventing laboratory-confirmed influenza (OR 0.77; 95% CI 0.44-1.34) with low certainty of evidence (Figure 3). The leave-one-out sensitivity analysis revealed no significant studies. No child or adolescent RCT directly compared quadrivalent LAIV with quadrivalent IIV; the only study compared quadrivalent LAIV to trivalent IIV (Figure 3).

In the subgroup of large, multi-center trials, LAIV was associated with significantly lower odds of influenza infection compared with IIV (OR 0.50; 95% CI 0.28-0.88) with a high certainty of evidence. By contrast, smaller studies tended to favor IIV, influenced primarily by two trials conducted among malnourished Indian children (79) and a Hutterite community (82) (Figure 4A).

Age-specific analysis suggested a trend toward better performance of LAIV in younger children, although this difference was not statistically significant (Figure 4B).



**Figure 3. Forest plot representing the OR with 95% CI for confirmed influenza cases, separating trivalent LAIV-IIV comparisons from the single quadrivalent LAIV versus trivalent IIV trial (1)**

Squares represent study-specific odds ratios (OR), with the center of the square indicating the point estimate and the horizontal line showing the 95% confidence interval (95% -

CI). The size of the squares is proportional to study weight. Diamonds represent pooled estimates.




Figure 4. Forest plots representing the OR with 95% CI for confirmed influenza cases (36)

A.) Subgroup analysis comparing large multicenter studies (>100 centers) with smaller studies (<100 centers).

B.) Subgroup analysis of children younger than 6 years of age.

Squares represent study-specific odds ratios (OR), with the center of the square indicating the point estimate and the horizontal line showing the 95% confidence interval (95% - CI). The size of the squares is proportional to study weight. Diamonds represent pooled estimates.

### **8.1.3. Secondary Outcomes**

#### **8.1.3.1. Safety**

Safety findings were derived from 19 trials, encompassing data from over 17,000 participants. We could report on a wide range of adverse events. (Table 3).

##### **a) Mortality**

No vaccination-related deaths were reported across the 8958 vaccinated participants (Table 3).

##### **b) Serious adverse events (SAEs)**

The incidence of SAEs was significantly higher following trivalent LAIV compared with trivalent IIV. However, if we focused on the number of individuals affected by adverse events, not on the overall event frequency, the difference was no longer significant (Table 3). Across the full dataset, only 23 vaccine-related SAEs were reported among 17,092 trivalent vaccine recipients. None by 741 quadrivalent recipients. Odds ratios did not differ significantly by vaccine type (trivalent: OR = 1.07, 95%CI = 0.70;1.62, quadrivalent: OR 0.92, 95%CI = 0.46;1.87), nor for children younger than nine years (Table 3).

##### **c) Hospitalizations**

In total, rates of hospitalizations were low (N = 316, LAIV: 1.29% vs. IIV: 1.34%) (Table 3).

##### **d) Adverse Events (AEs)**

When assessed by event frequency, trivalent LAIV was associated with fewer reported adverse events. However, when outcomes were analyzed according to the number of affected individuals, IIV demonstrated significantly lower odds (Table 3).

##### **e) Specific Adverse Events**

A total of 21 predefined adverse event categories were analyzed across trivalent trials (Table 3). A statistically significant difference emerged only for nasal symptoms, which were more frequently reported after LAIV (Table 3).

Two trivalent studies reported asthma exacerbations, both yielded non-significant differences (OR = 1.08, 95%CI = 0.90;1.29 and OR = 1.12, 95%CI = 0.78;1.60), although a meta-analysis was not feasible (76,88).

Specific adverse events associated with quadrivalent LAIV were reported infrequently. Only coughing (OR = 0.88, 95%CI=0.44;1.76) (95), significant wheezing (OR=0.62, 95%CI=0.31;1.21) and OR = 1.67, 95%CI=0.02;137.35) (93,96), and asthma exacerbations (OR = 0.70, 95%CI=0.26;1.90) (97) were available for comparison. None demonstrated statistically significant differences; the limited evidence also precluded meta-analytic synthesis.

**Table 3. Comparative safety outcomes of trivalent LAIV vs. IIV displayed in sequence of the level of GRADE and effect size (36)**

Lower odds for LAIV			Lower odds for IIV			
Outcome	OR (CI 95%)	GRADE	Outcome	OR (CI 95%)	GRADE	
			Nasal symptoms – large, multi-center studies	1.64 (1.33; 2.02)	High	Significant
			Nasal symptoms	1.55 (1.30; 1.86)	Moderate	
			Adverse events by the number of affected people	1.26 (1.14;1.40)	Moderate	
			Serious adverse events	1.17 (1.02;1.34)	Moderate	
Coughing	0.95 (0.86;1.05)	High	Significant wheezing	1.16 (0.86; 1.56)	High	Non-significant
Diarrhea	0.98 (0.83; 1.16)	High	Sore throat	1.14 (0.99; 1.32)	High	
Related serious adverse events under nine years of age	0.93 (0.53; 1.63)	Moderate	Vomiting	1.09 (0.78; 1.53)	Moderate	
Chills	0.74 (0.26; 2.11)	Low	Serious adverse events by number of affected people	1.11 (0.96;1.28)	Low	
Having a temperature higher than 38,5C	0.78 (0.37; 1.66)	Low	Decreased activity	1.02 (0.59; 1.76)	Low	
Headache	0.90 (0.62;1.31)	Low	Otitis media	1.48 (0.45; 4.89)	Very low	
Adverse events by the number of reported events	0.51 (0.05;5.09)	Very low	Upper respiratory tract infection	1.64 (0.27; 10.05)	Very low	
Muscle- or body ache	0.56 (0.24; 1.32)	Very low	At least subfebrility under six years of age	1.32 (0.46; 3.75)	Very low	
Hospitalization	0.58 (0.04;7.86)	Very low	Skin reactions	1.27 (0.14;11.65)	Very low	
Adverse events	0.81 (0.36;1.83)	Very low	Nasal symptoms – smaller studies	1.24 (0.89; 1.71)	Very low	
Fever	0.85 (0.50;1.43)	Very low	Nasopharyngitis	1.22 (0.53; 2.79)	Very low	
At least subfebrility above six years of age	0.91 (0.58; 1.43)	Very low	Irritability	1.08 (0.78; 1.49)	Very low	
At least subfebrility	0.93 (0.54; 1.61)	Very low	Related serious adverse events	1.07 (0.70;1.62)	Very low	
Decreased appetite	0.94 (0.66; 1.35)	Very low	Ear or eye reactions	1.06 (0.47; 2.40)	Very low	
Wheezing	0.98 (0.73; 1.33)	Very low				

OR: odds ratio; CI:confidence interval; LAIV: live-attenuated influenza vaccine; IIV: inactivated influenza vaccine; GRADE: Grading of Recommendations Assessment, Development and Evaluation.


### 8.1.3.2. Cost-effectiveness

All three analyses, which were based on previous RCTs, reached a uniform conclusion, indicating that LAIV is the more cost-effective option (Table 2). However, we were unable to perform a quantitative synthesis due to the lack of reporting confidence intervals in two out of three studies. According to the trials, LAIV's higher protection rate resulted in fewer healthcare visits and reduced caregiver productivity loss. These advantages outweighed the higher unit cost of LAIV across all modeled scenarios (83,85,87). No cost-effectiveness evaluations were identified for quadrivalent vaccine comparisons.

### 8.1.4. Risk of Bias Assessment

Most efficacy trials were judged to have a low risk of bias. In contrast, the safety dataset demonstrated more variability in methodological rigor. Six of the nineteen studies were judged to have an overall high risk of bias, most commonly due to incomplete outcome reporting or unclear ascertainment of adverse events.

Visual inspection of funnel plots did not suggest substantial asymmetry (Figure 4), and Egger's test for the "at least subfebrility" outcome did not indicate evidence of small-study effects ( $t = -0.13$ ,  $df = 8$ ,  $p = 0.90$ ).



**Figure 4. Funnel plots assessing potential publication bias for safety outcomes:** (A) nasal symptoms; (B) vaccine-related serious adverse events; (C) at least subfebrility; and (D) at least subfebrility, subgroup analysis by age (<6 years vs  $\geq 6$  years) (36)

Each dot represents an individual study. The vertical line indicates the pooled effect estimate, and diagonal lines represent the 95% pseudo–confidence limits.

#### **8.1.5. *Quality of Evidence***

Using the GRADE framework, the certainty of evidence supporting greater efficacy of trivalent LAIV, particularly when informed by large, multi-center randomized controlled trials, was rated as high. In contrast, safety outcomes showed substantially lower certainty. Among the 34 trivalent safety comparisons, over half (24/34) were graded as low or very low (Table 3). All safety outcomes related to quadrivalent formulations were graded as very low certainty, reflecting sparse data and wide confidence intervals (36).

#### **8.1.6. *Quality of Evidence***

Using the GRADE framework, the certainty of evidence supporting greater efficacy of trivalent LAIV, particularly when informed by large, multi-center randomized controlled trials, was rated as high. In contrast, safety outcomes showed substantially lower certainty. Among the 34 trivalent safety comparisons, over half (24/34) were graded as low or very low (Table 3). All safety outcomes related to quadrivalent formulations were graded as very low certainty, reflecting sparse data and wide confidence intervals.

### **8.2. Study II – Long COVID**

#### **8.2.1. *Study Population***

During the study period, 103 children were evaluated, of whom six did not meet the NICE criteria (44).

Prior to their first appointment, 80 of 86 tested children (83%) had laboratory evidence of SARS-CoV-2 infection. Among these, 48 of 58 (83%) were PCR-positive, 15 of 33 (45%) were rapid antigen test-positive, and 26 of 29 (90%) were IgG-seropositive. At the first visit, IgG antibodies were detected in 78 of 96 children (80%). Overall, laboratory confirmation of prior infection was available in 89 of 97 cases (92%). Thus, our study cohort consisted of 89 children.

The cohort had a mean age of  $11.4 \pm 3.8$  years, ranging from preschool age to late adolescence, with a notable female predominance (63%) (Table 4). Most experienced a mild or asymptomatic acute COVID-19 (94%), and a minority of five children had a moderate disease. None had received the SARS-CoV-2 vaccination before their first visit.

**Table 4. Patient characteristics (41)**

Characteristics	Overall	(%)	Male	(%)	Female	(%)	P <sup>Male vs. Female</sup>	g/r [95% CI]
<b>Ethnicity, n</b>								
Caucasian	89	(100)	33	(37)	56	(63)		
<b>Mean age, years (SD)</b>	11.4	(3.8)	10.1	(4.2)	12.3	(3.2)	<b>0.015</b>	0.60 [0.16;1.03]
<b>Age groups, n</b>								
0-5 years	6	(6)	6	(18)	0	(0)		
6-11 years	36	(40)	13	(40)	23	(41)		
12-18 years	47	(56)	14	(46)	33	(59)		
<b>Long COVID symptoms per children, n (SD)<sup>a</sup></b>	12	(8)	10	(8)	13	(7)	0.11	0.34 [-0.08;0.79]
<b>Mean symptom duration, weeks (SD)</b>	18	(8)	15	(7)	20	(8)	<b>0.003</b>	0.66 [0.21;1.10]
<b>Long COVID complaints related to an organ system, n</b>								
General	77	(87)	30	(91)	47	(84)	0.52	0.1 [-0.11;0.31]
Neurologic	74	(83)	26	(79)	48	(86)	0.40	0.09 [-0.12;0.30]
Mental	64	(72)	18	(55)	46	(82)	<b>0.007</b>	0.31 [0.09;0.52]
Cardiovascular	55	(62)	20	(61)	35	(63)	0.86	0.02 [-0.13;0.23]
Gastrointestinal	53	(60)	18	(55)	35	(63)	0.51	0.08 [-0.13;0.29]
ENT-O	49	(55)	13	(39)	36	(64)	<b>0.028</b>	0.25 [0.03;0.46]
Musculoskeletal	40	(45)	13	(39)	27	(48)	0.51	0.09 [-0.12;0.29]
Pulmonary	30	(34)	10	(30)	20	(36)	0.65	0.06 [-0.15;0.26]
Dermatologic	23	(26)	12	(36)	11	(20)	0.13	0.19 [-0.02;0.40]
Reproductive <sup>b</sup>	11	(12)	0	(0)	11	(20)		
<b>Occurrence of Long COVID symptoms after acute COVID-19 disease, n</b>								
continuously present	58	(65)	25	(76)	33	(59)		
1-2 weeks later	9	(10)	3	(9)	6	(11)		
3-4 weeks later	13	(15)	3	(9)	10	(18)		
>1 month later	9	(10)	2	(6)	7	(12)		
<b>Quality of long COVID complaints, n</b>								
Completely new complaint	73	(82)	26	(79)	47	(84)		
Change in the intensity/ quality	10	(11)	3	(9)	7	(12)		
Not clear	6	(7)	4	(12)	2	(4)		

CI: confidence interval, g/r: group ratio; ENT-O = ear-nose-throat & ophthalmology, n: number of people, p: p- value, SD: standard deviation

<sup>a</sup> The number of reported symptoms could not exceed 50.

<sup>b</sup> Only two questions addressed the complaints in the reproductive system: if they had erectile dysfunction, and if they had dysmenorrhea, and only dysmenorrhea occurred. Therefore, the comparison of the gender distribution in this category is biased.


## 8.2.2. Primary Outcomes

### 8.2.2.1. Symptom scale

Symptom duration at the time of first clinical evaluation ranged from 5 weeks to 37 weeks (9.3 months), with an average of 4.5 months. More than half of the children (65%) reported that at least one symptom had been continuously present since their acute illness, while an additional group developed symptoms weeks after recovery from the acute

infection, including 10% whose complaints emerged more than one month later (Table 4). The average number of reported persistent symptoms was 12 per child (range 1-33), involving a mean of five organ systems (Table 4).

Across the registry, persistent fatigue was the most prevalent symptom, reported by 70% of participants. Other high-frequency complaints included loss of interest or pleasure, headaches, concentration difficulties, dizziness, sleep disturbances, and post-exertional malaise. Chemosensory disorders, including alterations in smell or taste, were reported in 28% of cases (Figure 5).



**Figure 5. Distribution of symptom severity among children with long COVID (41)**

Symptom severity was assessed using a standardized scale, with stacked bars indicating the proportion of children reporting increasing levels of severity for each symptom.

### 8.2.2.1. Corresponding medical findings

We conducted more than 300 medical examinations to investigate the causes of the symptoms (Table 5). At least mild, objective clinical findings were documented in approximately one-quarter of cases (Table 5). Organ-specific diagnostic evaluations revealed that 18% of symptoms corresponded to objective medical findings within their respective symptom category (Table 5). Positive findings connected to complaints were most frequently identified in the respiratory category (38%) (Table 5).

**Table 5. Frequency of investigations by organ-specific complaint, including rates of positive and symptom-concordant findings (41)**

Number of patients with at least one group specific COMPLAINT	Examination	Positive findings/ Performed examinations (positive findings %)	Number of patients with at least one positive finding in the subgroup/number of patients with at least one group specific complaint, n (matching complaints %)
<b>GENERAL (n=77)</b>		<b>21/85 (25%)</b>	<b>21/77 (27%)</b>
	Neck US	7/9 (78%)	
	Thyroid screening	11/85 (12%)	
	6mWT <sup>a</sup>	10/29 (34%)	
<b>NEUROLOGIC (n=74)</b>		<b>5/44 (11%)</b>	<b>5/74 (7%)</b>
	Neurological examination	5/43 (12%)	
	Head MRI <sup>b</sup>	2/11 (18%)	
	Spinal MRI	0/1 (0%)	
	CSF <sup>c</sup>	2/2 (100%)	
	EEG	0/7 (0%)	
<b>MENTAL HEALTH (n=64)</b>		<b>15/24 (63%)</b>	<b>15/64 (23%)</b>
	Mental specialist consultation	15/24 (63%)	
<b>CARDIOVASCULAR (n=55)</b>		<b>8/44 (18%)</b>	<b>8/55 (15%)</b>
	Echocardiography	5/39 (13%)	
	Cardiac MRI	0/1 (0%)	
	ECG	4/44 (9%)	
	Holter ECG	0/2 (0%)	
<b>GASTROINTESTINAL (n=53)</b>		<b>8/37 (22%)</b>	<b>8/53 (15%)</b>
	Abdominal US	6/35 (17%)	
	Celiac disease screening	0/11 (0%)	
	Stool occult blood test	0/12 (0%)	
	Stool culture	0/10 (0%)	
	H <sub>2</sub> breath test	2/2 (100%)	

**Table 5. Frequency of investigations by organ-specific complaint, including rates of positive and symptom-concordant findings (continued) (41)**

Number of patients with at least one group specific COMPLAINT	Examination	Positive findings/ Performed examinations (positive findings %)	Number of patients with at least one positive finding in the subgroup/number of patients with at least one group specific complaint, n (matching complaints %)
<b>EAR-NOSE-THROAT &amp; OPHTHALMOLOGY (n= 49)</b>			
	ENT specialist consultation	3/16 (19%)	
	Ophthalmology specialist	7/32 (22%)	
<b>MUSCULOSKELETAL (n=45)</b>			
	Knee US	2/3 (67%)	
	Other imaging examinations <sup>d</sup>	1/2 (50%)	
<b>PULMONARY (n=30)</b>			
	Chest CT	0/3 (0%)	
	Pulmonary US	0/1 (0%)	
	Chest X-Ray	4/33 (12%)	
	Lung function test	11/24 (46%)	
<b>DERMATOLOGIC (n=23)</b>			
	Dermatology specialist consultation	5/8 (63%)	5/25 (20%)
<b>TOTAL</b>			
		<b>83/328 (25%)</b>	<b>83/465 (18%)</b>
6mWT: 6-minute walking test, CSF: cerebrospinal fluid, CT: computed tomography, ECG: electrocardiogram, EEG: electroencephalogram, MRI: magnetic resonance imaging, US: ultrasound			
<sup>a</sup> Subject had to stop during the 6 minutes, or had a drop in SpO <sub>2</sub> <95%, or their heart rate elevated to 1.5x of their resting heart rate.			
<sup>b</sup> Positive MRIs were considered potentially normal variants by agreement between a radiologist and a pediatric neurology specialist.			
<sup>c</sup> Positive CSF samples showed only marginally elevated protein levels and were considered to be of low clinical importance by a pediatric neurology specialist. <sup>d</sup> Hip US, shoulder US, sternocostal MRI <sup>e</sup> Chest X-Rays were performed because of pulmonary and/or cardiological reasons.			

### 8.2.3. Secondary Outcomes

#### 8.2.3.1. Physical examination and laboratory testing

During physical examination, 51% of children had at least one detectable finding. Although most of them were mild, such as abdominal tenderness. Several clinically relevant signs were documented, including exercise intolerance, abnormal neurologic findings, cutaneous manifestations, and cardiopulmonary abnormalities. Most laboratory deviations were mild or of uncertain clinical significance. The positivity rate of performed imaging examinations was 28%.

#### 8.2.3.2. Autoimmune thyroiditis

Based on elevated thyroid autoantibodies, we found ten children with thyroid autoimmunity (12%) (Table 5). Four children also had elevated TSH levels.

Based on confirmatory ultrasound, the rate of newly diagnosed autoimmune thyroiditis was 7%.

#### **8.2.3.3. Cardio-pulmonary assessments**

Pulmonary examinations requested by our team yielded a relatively high diagnostic rate, with 46% of lung function tests showing abnormalities, almost all of which were attributed to obstructive pulmonary disease (Table 5).

Cardiology-directed examinations identified abnormalities in 15% of evaluated children, revealing isolated cases of suspected myocarditis, post-viral tachycardias, and a newly recognized long QT syndrome (Table 5).

Thirty-four percent of children completing a 6-minute walk test exhibited clinically significant findings (oxygen desaturation, need to stop, or substantial tachycardia).

#### **8.2.3.4. Neurologic evaluations**

Those who underwent neurology-related examinations were found to have non-physiologic findings in 7% with conditions such as trigeminal cephalalgia with polyneuropathy (Table 5).

#### **8.2.3.5. Gastrointestinal evaluations**

Among children with gastrointestinal complaints, who were referred for an abdominal ultrasound, celiac-, stool-, or breath testing, positive findings were detected in 15%, including lactose intolerance, dysbiosis, and hepatic steatosis (Table 5).

#### **8.2.3.6. Dermatologic consultations**

Dermatology specialist assessments led to positive findings in 63% of evaluated cases, including one child who had previously developed Schönlein-Henoch purpura, possibly associated with COVID-19 (Table 5).


#### **8.2.3.7. Mental health**

Mental health symptoms were common (reported by 72%), and formal evaluation resulted in new preliminary diagnoses in nearly one quarter of those assessed, most frequently with anxiety and depression (Figure 5,8, Table 5).

#### **8.2.3.8. Quality of Life (Functioning)**

Among the 67 children who completed at least half of the questionnaire, mean functioning scores were mostly consistent with mild functional limitations ( $Mean = 27.1, SD = 22.8, \text{min-max: } 0-90.9$ ) (Figure 6A). Comparison with pre-COVID-19 functioning indicated a predominantly worsened functional status ( $Mean = 70.4, SD = 16.3, \text{min-max: } 45.8-100$ )

(Figure 6B). Notably, 26% of participants exhibited both moderate-to-severe functional impairment (QoL-F  $\geq 50$ ) and a clear decline relative to their pre-infection baseline (Figure 6C). The domains most frequently affected were emotional well-being, concentration, physical endurance (including prolonged walking or standing), and participation in school-related daily activities (Figure 6). The ability to perform self-care was evaluated using a separate item. Of the 73 children who responded, 21 (29%) reported impaired functioning, whereas 52 (71%) reported no change.




**Figure 6. Functional impairment among children with long COVID (41)**

- (A) Distribution of difficulties across 12 domains of daily functioning. Responses are shown on a five-level ordinal scale ranging from no difficulty to extreme difficulty or inability to perform the activity.
- (B) Self-reported change in the same domains compared with the pre-COVID period, categorized as better, unchanged, or worse.
- (C) Relationship between current functional difficulties (QoL-F score) and perceived change since COVID-19 (QoL-F change score).



### 8.2.5.2. Acute vs. long

As in acute COVID-19, general and neurological symptoms predominated at the lingering phase; however, mental and cardiologic complaints were more frequently reported in long COVID syndrome than during the acute phase (Figure 8).



**Figure 8. Comparison of symptom category frequencies during acute COVID-19 and long COVID within the same cohort of children (41)**

Frequencies indicate the percentage of children reporting at least one symptom within each organ-system category at each disease phase.

ENT-O: ear–nose–throat/ophthalmologic

### 8.2.5.3. Diagnostic imaging

Low-dose computed tomography scans performed early in the clinic’s operation revealed no structural pulmonary abnormalities, leading to a shift toward non-radiation investigations.

## 9. DISCUSSION

### 9.1. Summary of Findings, International Comparisons

Through two complementary studies, a large-scale systematic review and meta-analysis of pediatric influenza vaccines and a registry analysis of children with long COVID syndrome, this work sought to advance the understanding of pediatric viral infections by addressing preventive strategies and post-infectious long-term outcomes. Collectively, our findings highlight two central challenges in pediatric viral infection control: optimizing effective preventive interventions and strengthening health care systems to address prolonged, multisystem morbidity following acute viral infections.

#### 9.1.1. *Prevention: Influenza Vaccination*

Our systematic review and meta-analysis of head-to-head randomized controlled trials, comprising data on more than 15,000 children, demonstrated that trivalent LAIV and IIV show similar overall efficacy in preventing laboratory-confirmed influenza in children. However, when data were restricted to large, multicenter trials, LAIV showed superiority over IIV, suggesting enhanced real-world performance in more diverse, representative populations. Similarly, a recent network meta-analysis of pediatric observational studies indicated comparable moderate overall effectiveness for both vaccine types with varying strain-specific performance over seasons (98,99). More specifically, no significant difference in vaccine effectiveness against all influenza strains was observed between 2019 and 2023 for the quadrivalent live attenuated influenza vaccine (61.9% (95% CI, 53.0–69.1)) and the quadrivalent inactivated influenza vaccine (45.7% (95% CI, 33.2–55.8)) (99). Extending the timeframe from 2003 to 2023, another study found that vaccine effectiveness was similar across vaccine types, with pooled estimates approximately 50% (98).

Protection against influenza-associated hospitalization in children was moderate (53.3%, 95% CI 47.2–58.8), according to a meta-analysis of 37 test-negative studies, with higher effectiveness observed against A/H1N1pdm09 and in antigenically well matched seasons. (100).

The heterogeneity observed in our study across smaller trials is consistent with global variability in vaccination impact, as effectiveness may differ by influenza season based on the circulating virus subtype and the vaccine's strain-specific effectiveness (98).

Factors, such as host-specific variables, including nutritional status, pre-existing immunity, immunosuppressive conditions, and sociocultural determinants, have also been shown to modulate immunogenicity and clinical effectiveness (101–104).

The safety profile across more than 17,000 children was reassuring, as no vaccine-related deaths and only 23 vaccine-related serious adverse events were observed, with no significant difference between LAIV and IIV. This aligns with global pharmacovigilance data, which confirms that vaccines are among the safest interventions in pediatric care (105–107).

Economic evaluations consistently favored LAIV due to reductions in influenza incidence, healthcare utilization, and parental productivity loss. According to a recent systematic review, cost-effectiveness appears to be primarily driven by vaccine effectiveness, coverage rates, herd immunity, and local economic parameters, and both influenza vaccines are cost-effective, suggesting tailored decision-making for authorities (108).

### ***9.1.2. Long COVID***

Our registry analysis of 89 Hungarian children with long COVID revealed substantial and persistent multisystem morbidity following SARS-CoV-2 infection at our single-center, descriptive early pandemic study. Based on our study, we were unable to determine prevalence estimates. International data remain highly variable, ranging from <1% to >40% across studies, reflecting heterogeneity in case definitions, study populations, symptom assessment methods, reliance on self-reported data, and the availability and selection of control groups (109).

Despite predominantly mild acute disease, affected children experienced a high burden of concurrent symptoms involving general, neurological, cardiopulmonary, gastrointestinal, and mental health domains, with measurable impact on everyday functioning in our cohort. In contrast, a recent meta-analysis comparing infected children with controls identified significantly increased risk only for persistent dyspnea, anosmia/ageusia, and fever. In our cohort, a subset of patients reported extensive multisystem complaints that persisted for a median of 4.5 months at the time of first evaluation, a point when the expected duration and prognosis of long COVID in children were still poorly defined. More recent international data suggest that the long-term

prognosis is favorable for most children, with symptom resolution occurring within approximately six months (109,110).

Our cohort showed an approximately 2:1 female-to-male ratio, with females reporting a higher symptom burden, consistent with studies identifying female sex, older age, and comorbidities as risk factors for persistent symptoms (111). The predominance of school-aged children also mirrors other international reports (112). Furthermore, we hypothesized that symptom profiles differ by age, particularly between younger and older children, a notion subsequently supported by findings from the large-scale “Researching COVID to Enhance Recovery” (RECOVER) – Pediatrics cohort (113,114).

We observed a pronounced mismatch between symptom burden and objective clinical findings, consistent with international reports suggesting that distinguishing post-COVID-related symptoms from pandemic-associated psychosocial effects is challenging (41,115). However, to our knowledge, no similar clinically oriented, but larger-scale controlled pediatric clinical study with laboratory-confirmed COVID-19 has been published to date.

Nevertheless, in a minority of cases, clinically significant conditions with potential therapeutic implications, such as autoimmune thyroiditis or obstructive respiratory disorders, were identified in our cohort. At the same time, certain diagnoses identified during evaluation, such as long QT syndrome, are not typically considered part of the pediatric long COVID spectrum (116). These findings likely reflect coincidental or previously unrecognized conditions rather than SARS-CoV-2-associated sequelae, highlighting the importance of comprehensive diagnostic assessment.

Following our initial observations, substantial further research, including work by our own research group, has explored potential links between SARS-CoV-2 infection and autoimmune conditions such as autoimmune thyroiditis, type 1 diabetes, and celiac disease (117–119). Although we could not demonstrate a causal association between COVID-19 and thyroid autoimmunity, in our subsequent study, we reported a prevalence of thyroid autoimmunity of 6.6% and autoimmune thyroiditis of 4.0% among 458 individuals, with long-term alterations present in the majority (117). Moreover, one of our early observational reports described higher incidence rates of type 1 diabetes after the onset of the pandemic, which were subsequently corroborated by a meta-analysis (118,120). Our latest findings indicate a long-term rise in thyroid autoimmunity among

children with type 1 diabetes, but independent of SARS-CoV-2 infection (121). Although universal celiac screening, which we initiated in July 2021, revealed a higher-than-expected prevalence of newly diagnosed celiac disease, current evidence does not support SARS-CoV-2 infection as a trigger for celiac disease in children, suggesting that these findings are likely incidental or related to increased diagnostic intensity (119,122).

Current evidence suggests that long COVID is a multifactorial condition with overlapping pathogenic mechanisms, including viral persistence, immune dysregulation with or without latent virus reactivation, alterations in the microbiome, autoimmunity, endothelial and microvascular dysfunction, neuroautonomic disturbances, and mitochondrial impairment (123,124). In parallel, our working group conducted a detailed clinical and immunological study, demonstrating a higher symptom burden and significantly reduced functioning in children with long COVID compared to convalescent controls. We also identified impaired neutrophil function that correlated with symptom severity, supporting a potential role for innate immune dysfunction in the pathophysiology or susceptibility to pediatric long COVID. Although a controlled design was applied, the number of children considered SARS-CoV-2-naïve at enrollment was limited, as a substantial proportion subsequently tested positive for prior infection, resulting in a small true-negative control group. (125).

### ***9.1.3. Integrated Perspective***

Taken together, these studies underscore that effective prevention of viral infections in childhood is critical not only for reducing acute morbidity but also for potentially limiting long-term sequelae. However, evidence on the role of vaccination in preventing long COVID remains heterogeneous, with current data providing only low-level support for a protective effect (126).

## **9.2. Strengths**

Together, these studies offer a uniquely integrated perspective on pediatric viral infections. Our work addresses critical gaps in pediatric infectious disease research, employs robust and transparent methodologies, and provides results directly relevant to clinical care and public health policy.

Our systematic review included only randomized controlled trials, the highest level of evidence for evaluating the causality of interventions and their outcomes. This design

minimized confounding and selection bias, allowing for a rigorous comparison between LAIV and IIV. The analysis incorporated large multicenter trials from diverse geographic regions, thereby enhancing the generalizability of the findings and reflecting real-world epidemiological conditions more accurately than single-center studies. Adherence to PRISMA guidelines, PROSPERO, the use of RoB2 and GRADE frameworks, and the incorporation of sensitivity analyses ensured transparency and methodological rigor. Finally, we evaluated not only efficacy but also safety and cost-effectiveness, enabling a multidimensional assessment of both vaccines within a unified framework. This comprehensive approach allows for more meaningful policy translation than efficacy estimates alone.

The long COVID study's primary strength lies in its timing, conducted early in the "long COVID era". Another strong point is its systematic approach and the in-person, clinician-led assessment using a standardized protocol. Unlike many international long COVID cohorts that rely solely on parent- or self-reported symptoms, this study incorporated detailed history-taking, physical examination, laboratory testing, imaging, and targeted specialist evaluations. Conducting the study early in the pandemic reduced bias related to prior vaccination and reinfection. Symptoms were precisely categorized into organ-system groups, and their frequency, intensity, duration, and co-occurrence patterns were systematically documented. More than 300 symptom-driven diagnostic pathways were evaluated (Table 5). This level of structured clinical assessment is rarely available in pediatric long COVID studies, positioning the dataset as one of the more detailed pediatric cohorts published to date. The inclusion of quality-of-life assessments, evaluated using standardized tools and the comparison to pre-COVID status, adds further value.

### **9.3. Limitations**

#### ***9.3.1. Influenza Vaccination***

Heterogeneity across trials related to population characteristics, circulating strains, antigenic match, and study period might limit the precision of pooled estimates. Direct quadrivalent-to-quadrivalent efficacy comparisons were unavailable; quadrivalent-to-quadrivalent safety data and quadrivalent-to-trivalent efficacy data were sparse, precluding definitive conclusions. However, recent guidance has returned to trivalent

vaccines, reflecting changes in circulating influenza B lineages and updated global vaccine strain selection strategies, thereby increasing the clinical relevance of our trivalent findings(127). Comparing only active-controlled studies substantially reduced the number of included trials, reflecting a shift toward test-negative designs that are less costly and more ethically feasible. Furthermore, the interpretation of active-controlled trials is challenging due to the absence of placebo comparators, underscoring the importance of concomitant placebo-controlled efficacy data for contextualizing comparative effectiveness results (128). The data did not allow robust age-stratified safety or efficacy analyses. Variation in reporting of adverse events and economic outcomes also constrained certain analyses. It should also be noted that our data on cost-effectiveness is based exclusively on modelling studies published more than a decade ago (83,85,87), and no contemporary economic evaluations based on head-to-head trials were identified. Given the substantial changes in the financial landscape, the applicability of our estimates to current settings is likely limited.

### **9.3.2. Long COVID**

We acknowledge that our cohort consisted of children presenting to a dedicated long COVID outpatient clinic and therefore likely represents a more symptomatic and/or health-seeking subgroup. However, no formal referral was required, which broadened access to care as awareness of pediatric Long COVID increased and more children with milder or previously unrecognized symptoms were evaluated. Moreover, current case definitions require persistent and functionally relevant symptoms to establish a diagnosis of long COVID. Consequently, children with very mild complaints would less likely to meet these criteria (46,47,49).

Nevertheless, during the two-year study period, more than 500 children were evaluated and followed up at our center, which served patients from across Hungary and functioned as a national referral site for pediatric long COVID care.

To reduce potential selection and misclassification biases, consecutive inclusion, predefined temporal criteria for Long COVID, and multidisciplinary case review were applied. Accordingly, the present analyses were limited to describing the clinical characteristics of children evaluated at our center, and no conclusions were drawn regarding population-level prevalence or risk among all SARS-CoV-2–infected children. This study was therefore designed as a descriptive, hypothesis-generating clinical

characterization rather than a comparative epidemiologic analysis, and no statistical weighting or post hoc population adjustment was performed.

The limitations of current diagnostic tools may lead to the omission of subtle abnormalities, resulting in a mismatch between symptoms and clinical findings. The cross-sectional nature of the first visit data restricts insight into longitudinal recovery trajectories. Families' recall of pre-pandemic health status may have introduced reporting bias, while symptom duration estimates and study participation may also have been influenced by the timing of clinic opening, limited capacity, and reliance on primarily online appointment registration.

## **10. CONCLUSIONS**

Taken together, our results emphasize the need for an integrated approach to pediatric infectious disease control that combines optimized preventive interventions with structured strategies for recognizing and managing long-term sequelae.

### **10.1. Study I. – Influenza vaccination**

Both trivalent LAIV and IIV are efficacious and safe in pediatric populations. Given the needle-free administration of LAIV and its higher acceptability, its use should be actively supported in appropriate pediatric settings, as increased uptake may enhance herd immunity and yield population-level and cost-effectiveness benefits.

### **10.2. Study II. – Long COVID**

In the absence of reliable biomarkers or targeted therapies, health policies must ensure equitable access to comprehensive pediatric long COVID services, as many affected children experience substantial functional and mental health impairment despite limited objective clinical findings. Potential increases in autoimmune disease prevalence underscore the need for ongoing surveillance and focused research.

## **11. IMPLICATIONS FOR PRACTICE**

### **11.1. Study I. - Influenza vaccination**

Our meta-analysis supports the consideration of LAIV as a central component of pediatric influenza prevention policies, given its comparable effectiveness and safety relative to IIV. The needle-free administration of LAIV represents an important implementation advantage, with the potential to improve acceptability among children and caregivers and to facilitate delivery in non-traditional settings (23,24,129,130). Regulatory approval for self- or caregiver-administration in the United States further underscores its potential to expand access (131).

### **11.2. Study II. – Long COVID**

Currently, no validated biomarker exists for pediatric long COVID, and until its long-term pathological sequelae are better understood, diagnosis remains one of exclusion. This approach often necessitates extensive investigations, placing considerable physical and psychological burden on affected children and their families (41,109).

Moreover, no disease-modifying causal therapy has yet been established for post-acute infection syndromes, including long COVID. Consequently, current management still relies on individualized, holistic care, emphasizing patient and family education, structured self-management strategies, and multimodal, multidisciplinary non-pharmacological interventions, with pharmacological treatment guided by symptom-specific recommendations (109,132).



## **12. IMPLICATIONS FOR RESEARCH**

### **12.1. Study I. – Influenza vaccination**

Until a “universal” influenza vaccination becomes available, there is a need for contemporary, adequately powered head-to-head trials comparing LAIV and IIV across multiple seasons and diverse populations. Because vaccine performance is strongly influenced by circulating strains, population characteristics, and contextual factors, future study designs must prospectively account for these variables with a particular emphasis on age and children from subtropical and tropical regions (101–104). Standardized reporting of outcomes, including efficacy, safety, and cost-effectiveness, would substantially improve comparability across trials. Evidence regarding the safety of LAIV in children under two years of age and in other high-risk groups, as children with asthma or wheezing, remains limited, highlighting the need for further pediatric safety studies (105,133). These areas are crucial for optimizing vaccine policy in a rapidly evolving viral landscape (57).

### **12.2. Study II. – Long COVID**

Our findings highlight the need for continued investigation into the biological mechanisms underlying persistent symptoms in pediatric long COVID. The identification of reliable biomarkers may enhance diagnostic accuracy, risk stratification, and the development of targeted therapeutic approaches (42). Future research should address the marked heterogeneity of symptom profiles through detailed phenotyping and determine which clinical features or symptom constellations justify more extensive evaluation. In addition, well-designed pediatric interventional studies and long-term follow-up cohorts are required to inform evidence-based management strategies and clarify disease trajectories.

## **13. IMPLICATIONS FOR POLICY MAKERS**

### **13.1. Study I. - Influenza vaccination**

Policy initiatives that address structural, financial, and behavioral barriers to vaccination have the potential to substantially increase pediatric vaccine uptake (57). Policymakers should therefore consider integrating LAIV as a key component of national pediatric influenza programs, particularly in settings with established immunization infrastructures, such as institute-based programs (24,36,134). High vaccination coverage among children is particularly impactful, as it reduces community transmission and provides indirect protection to high-risk populations (57). However, significant policy gaps persist, as LAIV remains unavailable or unfunded in many countries due to regulatory, reimbursement, and procurement constraints (25–28). In an era marked by global demographic change, vaccine hesitancy, and persistent influenza-associated morbidity, there is a need for context-specific vaccination policies that account for local epidemiology, seasonality, and health system capacity, rather than reliance on a uniform global approach (30,135).

### **13.2. Study II. – Long COVID**

The findings of this study highlight the need for coordinated, internationally harmonized pediatric long COVID care pathways and emphasize that health systems must recognize long COVID as a condition that can affect children even after mild acute infection. This is why we contributed to the work of the International Post-COVID-Condition in Children Collaboration (IP4C) (41,136). Policymakers should support the development of standardized clinical assessment frameworks to guide healthcare providers in managing children with persistent, fluctuating, and multisystem symptoms, especially given the limited diagnostic yield of routine investigations. Because many affected children experience reduced functional capacity, emotional symptoms, and school difficulties, health policy must prioritize access to multidisciplinary care, integrating pediatrics, mental health, rehabilitation, and educational support services. Ensuring that such care is available and equitable is essential for mitigating long-term impacts on children’s daily functioning and well-being.

Policymakers should therefore promote the development and adoption of standardized criteria, encourage the creation of pediatric long COVID registries, and support research infrastructure that enables consistent data collection and international comparability.

We had the opportunity to investigate a post-viral syndrome in large cohorts, representing an unprecedented situation in the history of this field. The results obtained may contribute to a better understanding of related post-viral conditions, particularly in the context of identifying potential causal therapies.

Finally, there is a need for public health communication strategies that acknowledge the burden of such conditions. Transparent guidance for families, schools, and clinicians is essential to enhance awareness, reduce stigma, and facilitate the early identification of children who may benefit from evaluation or support (41,55,109,112,132,136).

#### **14. FUTURE PERSPECTIVES**

In the short term, a new ethical approval has been obtained to further investigate neutrophil alterations in children with long COVID longitudinally. In parallel, we have developed a Hungarian national pediatric quality-of-life questionnaire that incorporates multiple domains and elements, adapted from established international instruments. This tool will enable the establishment of national reference values and facilitate comparisons between children living with chronic conditions and healthy peers. I would like to continue learning and gain further experience, ideally also within an international research environment.

## 15. REFERENCES

1. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis*. 2017 Nov 1;17(11):1133–61. doi:10.1016/S1473-3099(17)30396-1 PubMed PMID: 28843578.
2. The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. *Geriatrics*. *JAMA Internal Medicine*. *JAMA Network* [Internet]. [cited 2026 Jan 2]. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215118>
3. Zar HJ, Cacho F, Kootbodien T, Mejias A, Ortiz JR, Stein RT, et al. Early-life respiratory syncytial virus disease and long-term respiratory health. *Lancet Respir Med*. 2024 Oct 1;12(10):810–21. doi:10.1016/S2213-2600(24)00246-7 PubMed PMID: 39265601.
4. Singer D, Wang Y, La EM, Gerber SI, Wu A, Betts KA. Long-term clinical outcomes after hospitalization for acute respiratory illness due to respiratory syncytial virus (RSV). *Clin Infect Dis*. 2025 Dec 23;ciaf710. doi:10.1093/cid/ciaf710
5. Janas PP, Rozario C, Lucas CD, Hiemstra PS, Schwarze J, Chauché C. The long reach of influenza and other respiratory viruses: from acute epithelial injury to post-viral lung disease. *Clin Microbiol Rev*. 2025 Sep 11. Located at: 1752 N St., N.W., Washington, DC. doi:10.1128/cmr.00243-24
6. Lewnard JA, Malden DE, Hong V, Skela J, Feldstein LR, Saydah S, et al. Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults. *PLOS Med*. 2025 Oct 9;22(10):e1004777. doi:10.1371/journal.pmed.1004777
7. Antoon JW, Hall M, Herndon A, Johnson DP, Brown CM, Browning WL, et al. Prevalence, Risk Factors, and Outcomes of Influenza-Associated Neurologic Complications in Children. *J Pediatr*. 2021 Dec;239:32-38.e5. doi:10.1016/j.jpeds.2021.06.075 PubMed PMID: 34216629; PubMed Central PMCID: PMC8604779.
8. Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. *The Lancet*. 2022 Aug 27;400(10353):693–706. doi:10.1016/S0140-6736(22)00982-5 PubMed PMID: 36030813.
9. Narasimhan H, Wu Y, Goplen NP, Sun J. Immune determinants of chronic sequelae after respiratory viral infection. *Sci Immunol*. 2022 Jul 15;7(73):eabm7996. doi:10.1126/sciimmunol.abm7996 PubMed PMID: 35857581.
10. O’Sullivan O. Long-term sequelae following previous coronavirus epidemics. *Clin Med*. 2021 Jan 1;21(1):e68–70. doi:10.7861/clinmed.2020-0204

11. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. *Pediatr Infect Dis J*. 2020 May;39(5):355. doi:10.1097/INF.0000000000002660
12. Taborda I, Oben G, Santos Ferreira C, Alves Costa B, Curinha F, Tomé R, et al. Loss of Health-related Quality of Life Among Hospitalized Children With Respiratory Syncytial Virus and Their Caregivers. *Pediatr Infect Dis J*. 2026 Jan;45(1):29. doi:10.1097/INF.0000000000004973
13. Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Technical Report. *Pediatrics*. 2025 Sep 22;156(6):e2025073622. doi:10.1542/peds.2025-073622
14. Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement. *Pediatrics*. 2025 Sep 22;156(6):e2025073620. doi:10.1542/peds.2025-073620
15. Giovanetti M, Ali S, Slavov SN, Azarian T, Cella E, Giovanetti M, et al. Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges. *Microorganisms*. 2025 Feb 20;13(3). doi:10.3390/microorganisms13030469
16. Nisar N, Badar N, Safdar I. Assessing influenza activity variations in the Asian region during the pre- and post-pandemic period (2017–2023). *PLOS ONE*. 2025 Jun 4;20(6):e0323465. doi:10.1371/journal.pone.0323465
17. Jing S, Wang H. Infectivity and fatality of influenza in pre- and post-COVID-19 pandemic year. *PLOS Comput Biol*. 2025 Jul 8;21(7):e1013229. doi:10.1371/journal.pcbi.1013229 PubMed PMID: 40627783; PubMed Central PMCID: PMC12251249.
18. European Centre for Disease Prevention and Control, Alhaffar BA. Survey report on national seasonal influenza vaccination recommendations and coverage rates in EU/EEA countries, 2024/25 [Internet]. SE: European Centre for Disease Prevention and Control; 2025 [cited 2026 Mar 6]. Available from: <https://data.europa.eu/doi/10.2900/4170165> doi:10.2900/4170165
19. EU recommendations for 2025/2026 seasonal flu vaccine composition. European Medicines Agency (EMA) [Internet]. 2025 [cited 2026 Jan 2]. Available from: <https://www.ema.europa.eu/en/news/eu-recommendations-2025-2026-seasonal-flu-vaccine-composition>
20. Research C for BE and. Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season. FDA [Internet]. 2024 Mar 5 [cited 2026 Jan 3]. Available from: <https://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza-season>

21. Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season [Internet]. [cited 2026 Jan 3]. Available from: <https://www.who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season>
22. Goldman RD, McGregor S, Marneni SR, Katsuta T, Griffiths MA, Hall JE, et al. Willingness to Vaccinate Children against Influenza after the Coronavirus Disease 2019 Pandemic. *J Pediatr.* 2021 Jan 1;228:87-93.e2. doi:10.1016/j.jpeds.2020.08.005 PubMed PMID: 32771480.
23. Gioia ERD, Porqueddu A, Nebiaj O, Bianconi A, Conni A, Montalti M, et al. The Role of Needle Fear in Pediatric Flu Vaccine Hesitancy: A Cross-Sectional Study in Bologna Metropolitan Area. *Vaccines.* 2022 Aug 25;10(9). doi:10.3390/vaccines10091388
24. Martín JJP, Moreno MZ, Miñarro FIT, Moreno MCG, Gómez M del CV, Martínez MP, et al. Influenza Vaccination in Children Younger than 5 Years in the Region of Murcia (Spain), a Comparative Analysis among Vaccinating and Non-Vaccinating Parents: Data from the FLUTETRA Study. *Vaccines.* 2024 Feb 13;12(2). doi:10.3390/vaccines12020192
25. 2024 Seasonal influenza vaccines | Therapeutic Goods Administration (TGA) [text] [Internet]. Therapeutic Goods Administration (TGA); 2024 [cited 2026 Jan 2]. Available from: <https://www.tga.gov.au/resources/publication/corporate-reports/2024-seasonal-influenza-vaccines>
26. Nogareda F, Gharpure R, Contreras M, Velandia M, Lucia Pacis C, Elena Chevez A, et al. Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic. *Vaccine.* 2023 Jul 12;41(31):4554–60. doi:10.1016/j.vaccine.2023.06.024
27. Li J, Zhang Y, Zhang X, Liu L, Li J, Zhang Y, et al. Influenza and Universal Vaccine Research in China. *Viruses.* 2022 Dec 30;15(1). doi:10.3390/v15010116
28. Vaccine Scheduler. ECDC [Internet]. [cited 2026 Jan 2]. Available from: <https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1>
29. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season. *MMWR Morb Mortal Wkly Rep.* 2025;74. doi:10.15585/mmwr.mm7432a2
30. Aksoy N, Ozturk N, Agh T, Kardas P, Şahin B. Optimizing influenza prevention: a systematic review of the cost-effectiveness of pediatric vaccination programs and vaccine types. *Front Public Health.* 2025 Oct 30;13. doi:10.3389/fpubh.2025.1589403

31. Canada PHA of. Influenza vaccines: Canadian Immunization Guide [education and awareness;guidance] [Internet]. 2007 [cited 2026 Jan 4]. Available from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-10-influenza-vaccine.html>
32. CDC. Vaccines & Immunizations [Internet]. 2024 [cited 2026 Jan 2]. Contraindications and Precautions. Available from: <https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html>
33. Fluenz. European Medicines Agency (EMA) [Internet]. 2013 [cited 2026 Jan 2]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/fluenz-0>
34. Guo J, Chen X, Guo Y, Liu M, Li P, Tao Y, et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies. *Vaccine*. 2024 Mar 19;42(8):1883–91. doi:10.1016/j.vaccine.2024.02.059 PubMed PMID: 38423813.
35. Minozzi S, Lytras T, Gianola S, Gonzalez-Lorenzo M, Castellini G, Galli C, et al. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis. *EClinicalMedicine*. 2022 Apr;46:101331. doi:10.1016/j.eclinm.2022.101331 PubMed PMID: 35360146; PubMed Central PMCID: PMC8961170.
36. Garai R, Jánosi Á, Krivácsy P, Herczeg V, Kóti T, Nagy R, et al. Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis. *J Transl Med*. 2024 Oct 4;22(1):903. doi:10.1186/s12967-024-05676-9
37. Goldin S, Brooks D, Jorgensen P, Wijesinghe P, Cho H, Attia R, et al. Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022. *Vaccine*. 2024 Dec 2;42(26):126274. doi:10.1016/j.vaccine.2024.126274
38. Al Awaidi S, Abusrewil S, AbuHasan M, Akcay M, Aksakal FNB, Bashir U, et al. Influenza vaccination situation in Middle-East and North Africa countries: Report of the 7th MENA Influenza Stakeholders Network (MENA-ISN). *J Infect Public Health*. 2018 Nov 1;11(6):845–50. doi:10.1016/j.jiph.2018.07.003
39. Global Influenza Strategy 2019–2030 [Internet]. [cited 2026 Jan 3]. Available from: <https://www.who.int/publications/i/item/9789241515320>
40. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. *Eur J Pediatr*. 2022 Dec 1;181(12):3995–4009. doi:10.1007/s00431-022-04600-x
41. Garai R, Krivácsy P, Herczeg V, Kovács F, Tél B, Kelemen J, et al. Clinical assessment of children with long COVID syndrome. *Pediatr Res*. 2023 May;93(6):1616–25. doi:10.1038/s41390-022-02378-0

42. Krishna B, Wills M, Sithole N. Long COVID: what is known and what gaps need to be addressed. *Br Med Bull.* 2023 Sep 1;147(1):6–19. doi:10.1093/bmb/ldad016
43. Hua MJ, Butera G, Akinyemi O, Porterfield D. Biases and limitations in observational studies of Long COVID prevalence and risk factors: A rapid systematic umbrella review. *PLOS ONE.* 2024 May 2;19(5):e0302408. doi:10.1371/journal.pone.0302408
44. Venkatesan P. NICE guideline on long COVID. *Lancet Respir Med.* 2021 Feb 1;9(2):129. doi:10.1016/S2213-2600(21)00031-X PubMed PMID: 33453162.
45. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. *BMJ.* 2021 Jan 22;372:n136. doi:10.1136/bmj.n136 PubMed PMID: 33483331.
46. Stephenson T, Allin B, Nugawela MD, Rojas N, Dalrymple E, Pereira SP, et al. Long COVID (post-COVID-19 condition) in children: a modified Delphi process. *Arch Dis Child.* 2022 Jul 1;107(7):674–80. doi:10.1136/archdischild-2021-323624 PubMed PMID: 35365499.
47. A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus, 16 February 2023 [Internet]. [cited 2026 Feb 15]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1>
48. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [Internet]. [cited 2026 Feb 15]. Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-Post\\_COVID-19\\_condition-Clinical\\_case\\_definition-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1)
49. Ely EW, Brown LM, Fineberg HV. Long Covid Defined. *N Engl J Med.* 2024 Nov 6;391(18):1746–53. doi:10.1056/NEJMs2408466
50. Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, Ziv A, Bar-On O, Birk E, et al. Long COVID in Children: Observations From a Designated Pediatric Clinic. *Pediatr Infect Dis J.* 2021 Dec;40(12):e509. doi:10.1097/INF.0000000000003285
51. Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *Eur Respir J.* 2022 Feb 3;59(2). doi:10.1183/13993003.01341-2021 PubMed PMID: 34210789.
52. Morand A, Campion JY, Lepine A, Bosdure E, Luciani L, Cammilleri S, et al. Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. *Eur J Nucl Med Mol Imaging.* 2022 Feb 1;49(3):913–20. doi:10.1007/s00259-021-05528-4
53. Erol N, Alpınar A, Erol C, Sari E, Alkan K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. *Cardiol Young.* 2022 Jul;32(7):1085–91. doi:10.1017/S1047951121003693

54. Buonsenso D, Giuda DD, Sigfrid L, Pizzuto DA, Sante GD, Rose CD, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. *Lancet Child Adolesc Health*. 2021 Sep 1;5(9):677–80. doi:10.1016/S2352-4642(21)00196-6 PubMed PMID: 34339624.
55. Panda PK, Gupta J, Chowdhury SR, Kumar R, Meena AK, Madaan P, et al. Psychological and Behavioral Impact of Lockdown and Quarantine Measures for COVID-19 Pandemic on Children, Adolescents and Caregivers: A Systematic Review and Meta-Analysis. *J Trop Pediatr*. 2020 Dec 27;fmaa122. doi:10.1093/tropej/fmaa122 PubMed PMID: 33367907; PubMed Central PMCID: PMC7798512.
56. Mansourian M, Ghandi Y, Habibi D, Mehrabi S. COVID-19 infection in children: A systematic review and meta-analysis of clinical features and laboratory findings. *Arch Pédiatrie*. 2021 Apr 1;28(3):242–8. doi:10.1016/j.arcped.2020.12.008
57. Bambery B, Douglas T, Selgelid MJ, Maslen H, Giubilini A, Pollard AJ, et al. Influenza Vaccination Strategies Should Target Children. *Public Health Ethics*. 2017 Dec 8;11(2):221–34. doi:10.1093/phe/phx021 PubMed PMID: 30135702; PubMed Central PMCID: PMC6093440.
58. Rao S, Gross RS, Mohandas S, Stein CR, Case A, Dreyer B, et al. Postacute Sequelae of SARS-CoV-2 in Children. *Pediatrics*. 2024 Feb 7;153(3):e2023062570. doi:10.1542/peds.2023-062570
59. Gross RS, Thaweethai T, Kleinman LC, Snowden JN, Rosenzweig EB, Milner JD, et al. Characterizing Long COVID in Children and Adolescents. *JAMA*. 2024 Oct 8;332(14):1174–88. doi:10.1001/jama.2024.12747
60. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLOS Med*. 2021 Mar 29;18(3):e1003583. doi:10.1371/journal.pmed.1003583
61. Jefferson T, Rivetti A, Pietranonj CD, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev*. 2018;(2). doi:10.1002/14651858.CD004879.pub5
62. Cochrane Handbook for Systematic Reviews of Interventions | Cochrane [Internet]. [cited 2026 Jan 3]. Available from: <https://www.cochrane.org/authors/handbooks-and-manuals/handbook>
63. GRADE handbook [Internet]. [cited 2026 Jan 3]. Available from: <https://gdt.gradepro.org/app/handbook/handbook.html>
64. Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel Haenszel odds ratio. *Am J Epidemiol*. 1986 Nov 1;124(5):719–23. doi:10.1093/oxfordjournals.aje.a114447

65. Mantel N, Haenszel W. Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease. *JNCI J Natl Cancer Inst.* 1959 Apr 1;22(4):719–48. doi:10.1093/jnci/22.4.719
66. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. *Stat Med.* 2001;20(24):3875–89. doi:10.1002/sim.1009
67. Paule RC, Mandel J. Consensus Values and Weighting Factors. *J Res Natl Bur Stand.* 1982 Sep;87(5):377. doi:10.6028/jres.087.022
68. Harrer M, Cuijpers P, Furukawa T, Ebert D. *Doing Meta-Analysis with R: A Hands-On Guide.* New York: Chapman and Hall/CRC; 2021. 500 p. doi:10.1201/9781003107347
69. Matrajt L, Halloran ME, Antia R. Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better? *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020 Mar 15;70(6):1029–37. doi:10.1093/cid/ciz358 PubMed PMID: 31056675; PubMed Central PMCID: PMC7319054.
70. Mohn KGI, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. *Hum Vaccines Immunother.* 2018 Jan 3;14(3):571–8. doi:10.1080/21645515.2017.1377376 PubMed PMID: 28933664; PubMed Central PMCID: PMC5861782.
71. Global COVID-19 Clinical Platform Case Report Form (CRF) for Post COVID condition (Post COVID-19 CRF) [Internet]. [cited 2026 Jan 3]. Available from: [https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-\(crf\)-for-post-covid-conditions-\(post-covid-19-crf-\)](https://www.who.int/publications/i/item/global-covid-19-clinical-platform-case-report-form-(crf)-for-post-covid-conditions-(post-covid-19-crf-))
72. Belongia E. Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents [Clinical trial registration] [Internet]. *clinicaltrials.gov*; 2018 Mar [cited 2026 Jan 3]. Report No.: NCT02250274. Available from: <https://clinicaltrials.gov/study/NCT02250274>
73. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J.* 2006 Oct;25(10):870–9. doi:10.1097/01.inf.0000237829.66310.85 PubMed PMID: 17006279.
74. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med.* 2007 Feb 15;356(7):685–96. doi:10.1056/NEJMoa065368 PubMed PMID: 17301299.
75. Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. *J Infect Dis.* 2011 Nov 15;204(10):1475–82. doi:10.1093/infdis/jir561 PubMed PMID: 21949042.

76. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With Asthma. *Pediatr Infect Dis J*. 2006 Oct;25(10):860. doi:10.1097/01.inf.0000237797.14283.cf
77. Hoft DF, Lottenbach KR, Blazevic A, Turan A, Blevins TP, Pacatte TP, et al. Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. *Clin Vaccine Immunol*. 2017;24(1). Located at: 27847366. doi:10.1128/cvi.00414-16
78. Ilyushina NA, Haynes BC, Hoen AG, Khalenkov AM, Housman ML, Brown EP, et al. Live attenuated and inactivated influenza vaccines in children. *J Infect Dis*. 2015 Feb 1;211(3):352–60. doi:10.1093/infdis/jiu458 PubMed PMID: 25165161; PubMed Central PMCID: PMC4296173.
79. Krishnan A, Dar L, Saha S, Narayan VV, Kumar R, Kumar R, et al. Efficacy of live attenuated and inactivated influenza vaccines among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial. *PLOS Med*. 2021 Apr 29;18(4):e1003609. doi:10.1371/journal.pmed.1003609
80. Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, et al. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination. *Vaccine*. 2015;33(38):4910–5. Located at: 26232348. doi:10.1016/j.vaccine.2015.07.044
81. Levin MJ, Song LY, Fenton T, Nachman S, Patterson J, Walker R, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. *Vaccine*. 2008 Aug 5;26(33):4210–7. doi:10.1016/j.vaccine.2008.05.054 PubMed PMID: 18597900; PubMed Central PMCID: PMC2615200.
82. Loeb M, L. Russell M, Manning V, Fonseca K, J.D. Earn D, Horsman G, et al. Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children. *Ann Intern Med* [Internet]. 2016 Aug 16 [cited 2026 Jan 3]. Located at: world. Available from: <https://www.acpjournals.org/doi/10.7326/M16-0513>
83. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. *Vaccine*. 2008 Jun 2;26(23):2841–8. doi:10.1016/j.vaccine.2008.03.046
84. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric

- experience. *Pediatr Infect Dis J*. 2001 Aug;20(8):733–40. doi:10.1097/00006454-200108000-00004 PubMed PMID: 11734733.
85. Cost-Effectiveness of Live Attenuated Versus Inactivated Influenza Vaccine Among Children | Pharmacy Times [Internet]. 2026 [cited 2026 Jan 3]. Available from: <https://www.pharmacytimes.com/view/cost-effectiveness-of-live-attenuated-versus-inactivated-influenza-vaccine-among-children>
  86. Sokolow AG, Stallings AP, Kercsmar C, Harrington T, Jimenez-Truque N, Zhu Y, et al. Safety of Live Attenuated Influenza Vaccine in Children With Asthma. *Pediatrics*. 2022 Apr 1;149(4):e2021055432. doi:10.1542/peds.2021-055432 PubMed PMID: 35342923; PubMed Central PMCID: PMC11235090.
  87. Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. *Clin Outcomes Res CEOR*. 2012 Oct 4;4:287–98. doi:10.2147/CEOR.S33444 PubMed PMID: 23055756; PubMed Central PMCID: PMC3468276.
  88. EudraCT Number 2004-000585-13 - Clinical trial results - EU Clinical Trials Register [Internet]. [cited 2026 Jan 3]. Available from: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000585-13/results>
  89. Allende M. A Phase 2, Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of FluMist® Compared With Trivalent Inactivated Vaccine (TIV) in Children 12 to <36 Months of Age [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2021 Sep [cited 2026 Jan 9]. Report No.: NCT00461981. Available from: <https://clinicaltrials.gov/study/NCT00461981>
  90. C. Immune Responses in Preterm and Full-Term Infants Following Live, Attenuated Influenza Vaccination [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2014 Aug [cited 2026 Jan 9]. Report No.: NCT01194297. Available from: <https://clinicaltrials.gov/study/NCT01194297>
  91. Treanor J. Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal Influenza Vaccines in Children [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2016 Nov [cited 2026 Jan 9]. Report No.: NCT01246999. Available from: <https://clinicaltrials.gov/study/NCT01246999>
  92. Belongia E. Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2018 Mar [cited 2026 Jan 9]. Report No.: NCT02250274. Available from: <https://clinicaltrials.gov/study/NCT02250274>
  93. Creech B. Clinical Study of the Safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in Children With Asthma of Varying Levels of Severity [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2021 Feb [cited 2026 Jan 9]. Report No.: NCT03600428. Available from: <https://clinicaltrials.gov/study/NCT03600428>

94. Immunological Response to Influenza Vaccination in Children, Adolescents, and Young Adults: A RCT of FluMist vs. Flucelvax [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2021 Sep [cited 2026 Jan 9]. Report No.: NCT03982069. Available from: <https://clinicaltrials.gov/study/NCT03982069>
95. Creech B. Clinical Study of the Safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in Children With Asthma of Varying Levels of Severity [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2021 Feb [cited 2026 Jan 8]. Report No.: NCT03600428. Available from: <https://clinicaltrials.gov/study/NCT03600428>
96. Immune Responses in Preterm and Full-Term Infants Following Live, Attenuated Influenza Vaccination [Clinical trial registration] [Internet]. [clinicaltrials.gov](https://clinicaltrials.gov); 2014 Aug [cited 2026 Jan 8]. Report No.: NCT01194297. Available from: <https://clinicaltrials.gov/study/NCT01194297>
97. Sokolow AG, Stallings AP, Kercksmar C, Harrington T, Jimenez-Truque N, Zhu Y, et al. Safety of Live Attenuated Influenza Vaccine in Children With Asthma. *Pediatrics*. 2022 Mar 28;149(4):e2021055432. doi:10.1542/peds.2021-055432
98. Stuurman AL, Enxing J, Gutiérrez AV, Gray CM, Sepúlveda-Pachón IT, Ubamadu E, et al. Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis. *Expert Rev Vaccines*. 2025 Dec 31;24(1):703–25. doi:10.1080/14760584.2025.2536087 PubMed PMID: 40697050.
99. Bandell A, Kassianos G, Dibben O, El Azzi G. Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023). *Vaccine X*. 2025 Aug 1;25:100666. doi:10.1016/j.jvacx.2025.100666
100. Boddington NL, Pearson I, Whitaker H, Mangtani P, Pebody RG. Effectiveness of Influenza Vaccination in Preventing Hospitalization Due to Influenza in Children: A Systematic Review and Meta-analysis. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2021 Nov 2;73(9):1722–32. doi:10.1093/cid/ciab270 PubMed PMID: 33772586.
101. Domnich A, Manini I, Calabrò GE, Waure C de, Montomoli E, Domnich A, et al. Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses. *Vaccines*. 2019 Dec 13;7(4). doi:10.3390/vaccines7040215
102. Hadler JL. Influenza-Related Hospitalizations and Poverty Levels — United States, 2010–2012. *MMWR Morb Mortal Wkly Rep*. 2016;65. doi:10.15585/mmwr.mm6505a1
103. Hodgson D, Sánchez-Ovando S, Carolan L, Liu Y, Hadiprodjo AJ, Fox A, et al. Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity. *Vaccine*. 2025 Jan 12;44:126579. doi:10.1016/j.vaccine.2024.126579

104. Wen F, Guo J, Huang S. A meta-analysis identified genes responsible for distinct immune responses to trivalent inactivated and live attenuated influenza vaccines. *J Cell Physiol.* 2019;234(4):5196–202. doi:10.1002/jcp.27327
105. Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux T, et al. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. *Vaccine.* 2015 Dec 30;The Safety of Influenza Vaccines in Children: an Institute for Vaccine Safety White Paper33:F1–67. doi:10.1016/j.vaccine.2015.10.080
106. Jefferson T, Rivetti A, Pietranonj CD, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev.* 2018;(2). doi:10.1002/14651858.CD004879.pub5
107. Miller ER, Moro PL, Cano M, Shimabukuro TT. Deaths following vaccination: What does the evidence show? *Vaccine.* 2015 Jun 26;33(29):3288–92. doi:10.1016/j.vaccine.2015.05.023
108. Aksoy N, Ozturk N, Agh T, Kardas P, Şahin B. Optimizing influenza prevention: a systematic review of the cost-effectiveness of pediatric vaccination programs and vaccine types. *Front Public Health.* 2025;13:1589403. doi:10.3389/fpubh.2025.1589403 PubMed PMID: 41246076; PubMed Central PMCID: PMC12611858.
109. Toepfner N, Brinkmann F, Augustin S, Stojanov S, Behrends U. Long COVID in pediatrics—epidemiology, diagnosis, and management. *Eur J Pediatr.* 2024 Apr 1;183(4):1543–53. doi:10.1007/s00431-023-05360-y
110. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. *Eur J Pediatr.* 2022 Apr;181(4):1597–607. doi:10.1007/s00431-021-04345-z PubMed PMID: 35000003; PubMed Central PMCID: PMC8742700.
111. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O’Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect.* 2022 Feb 1;84(2):158–70. doi:10.1016/j.jinf.2021.11.011 PubMed PMID: 34813820.
112. Ha EK, Kim JH, Han MY. Long COVID in children and adolescents: prevalence, clinical manifestations, and management strategies. *Clin Exp Pediatr.* 2023 Jun 19;66(11):465–74. doi:10.3345/cep.2023.00472 PubMed PMID: 37350170; PubMed Central PMCID: PMC10626026.
113. Gross RS, Thaweethai T, Salisbury AL, Kleinman LC, Mohandas S, Rhee KE, et al. Characterizing Long COVID Symptoms During Early Childhood. *JAMA Pediatr.* 2025 Jul 1;179(7):781–92. doi:10.1001/jamapediatrics.2025.1066
114. Gross RS, Thaweethai T, Kleinman LC, Snowden JN, Rosenzweig EB, Milner JD, et al. Characterizing Long COVID in Children and Adolescents. *JAMA.* 2024 Oct 8;332(14):1174–88. doi:10.1001/jama.2024.12747

115. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. *Eur J Pediatr.* 2022 Dec 1;181(12):3995–4009. doi:10.1007/s00431-022-04600-x
116. Lu D, Hu J, Qian J, Cheng F. Temporal variations in QTc interval during and after COVID-19 infection: a retrospective study. *BMC Cardiovasc Disord.* 2024 Dec 23;24(1):738. doi:10.1186/s12872-024-04405-w
117. Herczeg V, Garai R, Takács J, Kovács F, Luczay A, Hrapka E, et al. Thyroid disturbances after COVID-19 and the effect of vaccination in children: a prospective tri-center registry analysis. *Eur J Pediatr.* 2023 Oct;182(10):4443–55. doi:10.1007/s00431-023-05097-8 PubMed PMID: 37488409; PubMed Central PMCID: PMC10587318.
118. D’Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. *JAMA Netw Open.* 2023 Jun 30;6(6):e2321281. doi:10.1001/jamanetworkopen.2023.21281
119. PhD Scientific Days [Internet]. [cited 2026 Jan 8]. Available from: <https://phd.kmcongress.com/archive/2024/osszefoglalo/11697>
120. Anti-SARS-CoV-2 Seropositivity Among Children With Newly Diagnosed Type 1 Diabetes Mellitus: A Case-Control Study | *Indian Pediatrics* [Internet]. [cited 2026 Jan 4]. Available from: <https://link.springer.com/article/10.1007/s13312-022-2626-y>
121. Herczeg V, Muzslay E, Czipó D, Terkovics L, Takács J, Garai R, et al. Increasing prevalence of thyroid autoimmunity in childhood type 1 diabetes in the pre-COVID but not during the COVID era. *Front Endocrinol.* 2025 Jan 24;15. doi:10.3389/fendo.2024.1496155
122. Previous SARS-CoV-2 Infection Is Not Associated With Increased Celiac Disease Autoimmunity in Children and Adolescents - PubMed [Internet]. [cited 2026 Jan 8]. Available from: <https://pubmed.ncbi.nlm.nih.gov/37159249/>
123. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol.* 2023 Mar;21(3):133–46. doi:10.1038/s41579-022-00846-2
124. Nunn AVW, Guy GW, Brysch W, Bell JD, Nunn AVW, Guy GW, et al. Understanding Long COVID; Mitochondrial Health and Adaptation—Old Pathways, New Problems. *Biomedicines.* 2022 Dec 2;10(12). doi:10.3390/biomedicines10123113
125. Kovács F, Posvai T, Zsáry E, Kolonics F, Garai R, Herczeg V, et al. Long COVID syndrome in children: neutrophilic granulocyte dysfunction and its correlation with disease severity. *Pediatr Res.* 2025 Jul;98(1):301–13. doi:10.1038/s41390-024-03731-1

126. Green R, Marjenberg Z, Lip GYH, Banerjee A, Wisnivesky J, Delaney BC, et al. A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID. *Nat Commun.* 2025 Nov 24;16(1):10326. doi:10.1038/s41467-025-65302-0
127. CDC. Influenza (Flu) [Internet]. 2026 [cited 2026 Mar 10]. 2025–2026 Flu Season. Available from: <https://www.cdc.gov/flu/season/2025-2026.html>
128. Ainslie KEC, Riley S. Is annual vaccination best? A modelling study of influenza vaccination strategies in children. *Vaccine.* 2022 May 9;40(21):2940–8. doi:10.1016/j.vaccine.2022.03.065 PubMed PMID: 35410816.
129. Understanding Parental Attitudes toward Vaccination: Comparative Assessment of a New Tool and Its Trial on a Representative Sample in Hungary | MDPI [Internet]. [cited 2026 Jan 4]. Available from: <https://www.mdpi.com/2076-393X/10/12/2006>
130. Taddio A, Chambers CT, Halperin SA, Ipp M, Lockett D, Rieder MJ, et al. Inadequate pain management during routine childhood immunizations: the nerve of it. *Clin Ther.* 2009;31 Suppl 2:S152-167. doi:10.1016/j.clinthera.2009.07.022 PubMed PMID: 19781434.
131. Jhaveri R, Skolnik N, Bandell A. Systematic review of evidence on feasibility of administering intranasal live attenuated influenza vaccine at home. *Npj Vaccines.* 2025 Nov 23;10(1):272. doi:10.1038/s41541-025-01324-5
132. Noij L, Terheggen-Lagro S, Muselaers E, Whittaker E, Gosling J, Brackel C, et al. A Multidisciplinary Approach: Management and Rehabilitation of Children With Pediatric Post-COVID-19 Condition. *Pediatr Infect Dis J.* 2024 Sep 1;43(9):880–4. doi:10.1097/INF.0000000000004408 PubMed PMID: 38808972; PubMed Central PMCID: PMC11319073.
133. Bandell A, Giles L, Cervelo Bouzo P, Sibbring GC, Maniaci J, Wojtczak H, et al. Safety of LAIV Vaccination in Asthma or Wheeze: A Systematic Review and GRADE Assessment. *Pediatrics.* 2025 Apr 24;155(5):e2024068459. doi:10.1542/peds.2024-068459
134. Boddington NL, Mangtani P, Zhao H, Verlander NQ, Ellis J, Andrews N, et al. Live-attenuated influenza vaccine effectiveness against hospitalization in children aged 2–6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14–2015/16. *Influenza Other Respir Viruses.* 2022;16(5):897–905. doi:10.1111/irv.12990
135. Seasonal Influenza Vaccine Use in Low and Middle Income Countries in the Tropics and Subtropics [Internet]. [cited 2026 Jan 4]. Available from: <https://www.who.int/publications/i/item/9789241565097>
136. Brackel CLH, Noij LCE, Vijverberg SJH, Legghe CL, Maitland-van der Zee AH, van Goudoever JB, et al. International Care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward. *Pediatr Res.* 2024 Jul;96(2):319–24.

doi:10.1038/s41390-023-03015-0 PubMed PMID: 38287106; PubMed Central  
PMCID: PMC12378996.

## 16. BIBLIOGRAPHY

### 16.1. Publications Related to the Thesis

**Garai Réka**, Jánosi Ágoston, Krivácsy Péter, Herczeg Vivien, Kói Tamás, Nagy Rita, Imrei, Marcell, Párniczky Andrea, Garami Miklós, Hegyi Péter, Szabó Attila József

**Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis**

JOURNAL OF TRANSLATIONAL MEDICINE 22: 1 Paper: 903, 15 p. (2024)

Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) Rank: D1

Scopus - Medicine (miscellaneous) SJR Rank: D1

IF: 7,5

**Garai Réka**, Krivácsy Péter, Herczeg Vivien, Kovács Fanni, Tél Bálint, Kelemen Judit, Máthé Anna, Zsáry Eszter, Takács Johanna, Veres Dániel Sándor, Szabó Attila J

**Clinical assessment of children with long COVID syndrome**

PEDIATRIC RESEARCH 93: 6 pp. 1616-1625. (2023)

Scopus - Pediatrics, Perinatology and Child Health Rank: D1

IF: 3,1

### 16.2. Publications not Related to the Thesis

Gáborján Anita, Koscsó Gábor, **Garai Réka**, Tamás László, Vicsi Klára, Hacki Tamás

**Prevention of noise-induced hearing loss in children – evidence-informed recommendations for safe listening at events**

INTERNATIONAL JOURNAL OF AUDIOLOGY 64: 10 pp. 1017-1026. (2025)

Scopus - Linguistics and Language Rank: D1

Scopus - Speech and Hearing Rank: Q1

IF: 1,9

Herczeg Vivien, Muzslay Eszter, Czipó Diána, Terkovic Lili, Takács Johanna, **Garai Réka**, Kovács Fanni, Luczay Andrea, Körner Anna, Tóth-Heyn Péter

**Increasing prevalence of thyroid autoimmunity in childhood type 1 diabetes in the pre-COVID but not during the COVID era**

FRONTIERS IN ENDOCRINOLOGY 15 Paper: 1496155, 9 p. (2025)

Scopus - Endocrinology, Diabetes and Metabolism Rank: Q1

IF: 4,6

Hernádfői Márk Viktor, Koch Dóra Kornélia, Kói Tamás, Imrei Marcell, Nagy Rita, Máté Vanda, **Garai Réka**, Donnet Jessica, Balogh József, Kovács Gábor T, Párniczky Andrea, Hegyi Péter, Garami Miklós

**Burden of Childhood Cancer and the Social and Economic Challenges in Adulthood. A Systematic Review and Meta-Analysis**

JAMA PEDIATRICS 178: 6 pp. 548-566. (2024)

Scopus - Pediatrics, Perinatology and Child Health Rank: D1

IF: 18,0

Kovács Fanni, Posvai Tamás, Zsáry Eszter, Kolonics Ferenc, **Garai Réka**, Herczeg Vivien, Czárán Domonkos, Takács Johanna, Szabó Attila József, Krivácsy Péter, Csépanyi-Kömi Roland

**Long COVID syndrome in children: neutrophilic granulocyte dysfunction and its correlation with disease severity**

PEDIATRIC RESEARCH 98: 1 pp. 301-313. (2025)

Scopus - Pediatrics, Perinatology and Child Health Rank: D1

IF: 3,1

Herczeg Vivien\*, **Garai Réka\***, Takács Johanna, Kovács Fanni, Luczay Andrea, Hrapka Erzsébet, Krivácsy Péter, Hosszú Éva, Beniczky Nikolett Jusstina, Németh Ágnes, Szilágyi, Eszter Szabina, Pécsi Anna, Szabó Zsófia, Szabó Attila József, Tóth-Heyn Péter

**Thyroid disturbances after COVID-19 and the effect of vaccination in children: a prospective tri-center registry analysis**

EUROPEAN JOURNAL OF PEDIATRICS 182: 10 pp. 4443-4455. (2023)

Scopus - Pediatrics, Perinatology and Child Health Rank: Q1

IF: 3,0

\*first authors

## 17. ACKNOWLEDGEMENTS

I am deeply grateful for the opportunity to work in a field that, at the time it emerged, was largely unknown. Being involved in the early clinical and scientific exploration of pediatric long COVID was both an extraordinary privilege and a profound responsibility. The intense time pressure, the need to build a new multidisciplinary team, and the simultaneous commitment to high-quality patient care and rigorous scientific inquiry have been defining experiences in my professional life.

I would like to express my sincere gratitude to Professor Attila József Szabó, Director of the Pediatric Center, for his trust and unwavering support. I am especially thankful for his encouragement to pursue advanced clinical research training at Harvard and for his role in supporting the establishment of the Semmelweis Pediatric Research and Innovation Group, which aims to strengthen long-term clinical research activities. I am equally thankful to my direct supervisor, Dr. Péter Krivácsy, for his trust, encouragement of independence, and openness to creative discussion. Sharing both the professional challenges and the learning process of this period, and navigating this evolving clinical reality together, has been invaluable.

This unique situation also led to a close and formative collaboration with Dr. Vivien Herczeg. Working together so closely, building a research group from the ground up, and learning side by side has been of immeasurable value to me. Without her, I would certainly not be where I am today, and I hope that our collaboration has been equally meaningful for her. Remarkably, this period of intensive research coincided with both of us becoming mothers, adding another shared dimension to our journey.

I am profoundly grateful to my family. I thank my husband for his patience, encouragement, and unwavering support, and for allowing me the space to pursue research with such commitment, even when he did not always agree with the extent of the resources this work required. I am also deeply thankful to our parents for their continuous help, which ensured that our children were cared for with both physical and emotional security during this demanding period. I am especially grateful to my own parents, who have recognized my potential from an early age, passed on their creative genes to me, and raised me with a strong sense of independence and problem-solving skills. I am particularly grateful to Dr. Bálint Tél, whose scientific insight and guidance were instrumental during the early stages of my influenza research and whose conceptual

leadership in the long COVID research team was indispensable to the development of our first publication at a time when none of us held a PhD. I appreciate the thoughtful and inspiring feedback he gave on my thesis. I also thank Dr. Nóra Béres, a mentor who is becoming an important research partner, and from whom I continue to learn clarity and perspective.

Finally, I am grateful to all colleagues involved in the pediatric long COVID outpatient clinic and to those I had the opportunity to work with throughout my PhD years, including Dr. Fanni Kovács, with whom I continue to collaborate on basic research related to long COVID.